Genetic association analysis with survival phenotypes by Müller, Andrea Martina
  
From 
The Institute of Medical Information Processing, Biometry, and Epidemiology 
of the Ludwig-Maximilians-Universität, Munich, Germany 
Chair of Epidemiology: Prof. Dr. Dr. H.-Erich Wichmann 
and 
The Institute of Epidemiology, Helmholtz Zentrum München, German Research 
Center for Environmental Health (GmbH) 
Director: Prof. Dr. Dr. H.-Erich Wichmann 
 
Genetic association analysis with survival phenotypes 
 
 
Thesis Submitted for a Doctoral degree in Human Biology 
at the Faculty of Medicine Ludwig-Maxiimilians-University, 
Munich, Germany 
 
 
 
 
 
by 
Andrea Martina Müller 
From 
Munich, Germany 
2009 
  
 
 
With approval of the Medical Faculty 
of the University of Munich 
 
 
 
 
 
 
 
 
 
 
First Reviewer: Prof. Dr. Dr. H.-Erich Wichmann 
Second Reviewer: Prof. Dr. Ulrich Mansmann 
 Prof. Dr. Elke Holinski-Feder 
Co-supervision: Dr. Iris M. Heid 
Dean: Prof. Dr. med. Dr. h.c. M. Reiser, FACR, FRCR 
Date of the oral examination: 17.03.2009
 i 
 
Acknowledgements 
In first instance I want to thank Prof. Dr. Dr. H.-Erich Wichmann, head of the Institute 
of Epidemiology at the Helmholtz Zentrum München and Chair of Epidemiology at 
the Institute of Medical Information Processing, Biometry, and Epidemiology of the 
University of Munich, who not only encouraged and enabled the work on this thesis 
at his institute, but also offered a variety of opportunities to work in the field of genetic 
epidemiology on exciting projects with experienced partners. 
Furthermore, I thank my direct supervisor Dr. Iris Heid from the working group 
“Genetic Epidemiology” at the Institute of Epidemiology at the Helmholtz Zentrum 
München for initialising this methodological work, her continuous support, invaluable 
advice, fruitful discussions and project coordination within the GenStat group. 
I am also grateful to PD Thomas Illig, head of the working group “Biological Samples 
in Genetic Epidemiology” and interim head of the working group “Genetic 
Epidemiology” at the Institute of Epidemiology at the Helmholtz Zentrum München, 
who organised availability of genetic data for this thesis and encouraged close 
collaboration with the laboratory and other working groups. 
Through the multidisciplinarity of the work in the group “Genetic Epidemiology” I 
enjoyed the possibility to get involved into different projects and learn from different 
fields of epidemiology, medicine as well as genetics, which was only possible through 
the support of Prof. Dr. Dr. H.-Erich Wichmann, Dr. Iris Heid and PD Thomas Illig. 
Important issues for the discussion part of this thesis were brought up by Prof. Dr. 
Helmut Küchenhoff from the Institut für Statistik at the Ludwig-Maximilians-Universität 
of Munich and Prof. Dr. Heike Bickeböller from the Department of Genetic 
Epidemiology at the University of Göttingen, whom I want to thank as well as all 
partners who contributed their data for evaluation within this thesis. 
ii  
 
Special thanks go to all my current and former colleagues, from whom I want to 
especially emphasize Claudia Lamina, who contributed to this work through helpful 
discussions on statistical and programming issues. 
Last but not least I thank my family and friends who were always at hand with help 
and unbelievable patience. 
 iii 
 
Table of Contents 
 
Acknowledgements   ...................................................................................................... i
Table of Contents   ....................................................................................................... iii
1 Introduction   .......................................................................................................... 1
1.1 General Introduction   ..................................................................................... 1
1.2 Epidemiologic studies   ................................................................................... 2
1.2.1 Common study types in epidemiology   ................................................... 2
1.2.2 Terminology   .......................................................................................... 3
1.2.3 Statistical methods for analysis of association in epidemiologic studies   3
1.2.3.1 Methods for cross-sectional and case-control studies   .............................................. 3
1.2.3.2 Methods for cohort studies   ........................................................................................ 5
1.3 Background in genetics   .............................................................................. 11
1.3.1 The human genome   ............................................................................ 11
1.3.2 Single nucleotide polymorphisms   ........................................................ 14
1.3.2.1 Single nucleotide polymorphisms as genetic markers   ............................................ 14
1.3.2.2 Genotyping   .............................................................................................................. 15
1.3.2.3 Quality control   ......................................................................................................... 16
1.4 Genetic association studies   ........................................................................ 18
1.4.1 Localisation of phenotype-associated genetic variants   ....................... 18
1.4.2 Genetic effect models   ......................................................................... 19
1.4.2.1 Genetic effect model definition   ................................................................................ 19
1.4.2.2 Coding of SNP variables   ......................................................................................... 21
1.4.3 Methods to quantify the genetic effect   ................................................. 21
1.4.3.1 Estimation of genetic effect sizes   ............................................................................ 21
1.4.3.2 Quantification of the impact of genetic variants   ...................................................... 22
2 Impact of genetic variants on survival phenotypes   .............................................26
2.1 Aim of the study  .......................................................................................... 26
iv  
 
2.1.1 Genetic association analysis with survival phenotypes   ....................... 26
2.1.2 Measures of the impact of genetic variants on survival phenotypes   ... 27
2.1.3 Aim of this thesis   ................................................................................. 28
2.1.4 Literature search   ................................................................................. 29
2.1.4.1 Overview of available criteria   .................................................................................. 29
2.1.4.2 Criteria selection   ..................................................................................................... 31
2.2 Methods   ..................................................................................................... 31
2.2.1 The three selected criteria   ................................................................... 31
2.2.1.1 Criterion based on cumulated hazard (kd.norm)   ........................................................ 31
2.2.1.2 Criteria based on variation of individual survival curves (V and Vw)   ....................... 32
2.2.1.3 Criterion based on variation of Schoenfeld residuals (R²sch)   .................................. 34
2.2.2 Simulation studies   ............................................................................... 35
2.2.2.1 Simulation of genetic variants   ................................................................................. 35
2.2.2.2 Simulation of survival outcome   ............................................................................... 36
2.2.2.3 Simulation of censoring times   ................................................................................. 36
2.2.2.4 Extended simulation scenarios with continuous covariates   .................................... 37
2.2.2.5 Bivariate simulations with genetic variants and a continuous covariate   ................. 38
2.2.2.6 Statistical analysis and simulation summary  ........................................................... 38
2.2.3 Real data analysis   ............................................................................... 39
2.2.3.1 The KORA data S3/F3 for survival analysis  ............................................................ 39
2.2.3.2 Adding simulation of SNPs associated with mortality   ............................................. 41
2.2.3.3 Statistical analysis and the impact of the genetic variants   ...................................... 42
2.3 Results   ....................................................................................................... 43
2.3.1 Results from SNP simulation studies   .................................................. 43
2.3.1.1 Overview   ................................................................................................................. 43
2.3.1.2 Reasonable values in the range [0;1]   ..................................................................... 44
2.3.1.3 Dependence on the genetic effect size   ................................................................... 50
2.3.1.4 Dependence on censoring   ...................................................................................... 51
2.3.2 Results from simulations for a single continuous covariate   ................. 54
2.3.3 Results from combining a SNP with a strong continuous predictor   ..... 57
2.3.4 Results from real data analysis   ........................................................... 60
2.3.4.1 KORA, real SNP analysis  ........................................................................................ 60
2.3.4.2 Analysis of artificial SNPs in KORA   ........................................................................ 66
 v 
 
3 Discussion   ..........................................................................................................68
3.1 Overview   .................................................................................................... 68
3.2 Main results   ................................................................................................ 69
3.3 Criteria selection  ......................................................................................... 72
3.4 Criteria characterisation   ............................................................................. 73
3.4.1 Characteristics of kd.norm   ...................................................................... 73
3.4.2 Characteristics of V   ............................................................................. 75
3.4.3 Characteristics of R²sch   ........................................................................ 76
3.5 Outlook   ....................................................................................................... 77
3.5.1 Strengths and limitations   ..................................................................... 77
3.5.2 Possible applications and extensions of R²sch   ..................................... 78
3.6 Conclusion   ................................................................................................. 81
Summary   ...................................................................................................................83
Zusammenfassung   ....................................................................................................85
References   ................................................................................................................88
Appendix  ....................................................................................................................95
A1. List of publications and presentations   ....................................................... 96
A2. Curriculum vitae   ......................................................................................... 104
1  1. Introduction 
 
 
1 Introduction 
1.1 General Introduction 
One of the major goals of epidemiologic research is too improve insight into risk 
factors associated with disease and disease development the recent advances in 
genetics offer a good possibility to analyse whether subgroups of the general 
population suffer from a genetically determined increased baseline risk or 
predisposition to develop disease. Therefore, identification of genetic variants that 
show association to health conditions is of growing interest and gave rise to the field 
of genetic epidemiology. 
For several monogenic disorders, genetic variants have already been successfully 
identified and research is now focusing on complex polygenic disorders with high 
prevalence in the general population, e.g. type 2 diabetes, myocardial infarction, 
atherosclerosis and related parameters. For a better understanding of the disease 
causing mechanisms, it is important not only to measure whether genetic variants are 
of influence but also to quantify their impact on changes of health parameters.  
More and more population-based studies provide long follow-up in combination with 
genetic data. Therefore, it is now possible to not only analyse the risk to develop 
disease through case-control studies but also the time of disease onset in the 
general population through application of methods from survival analysis. Especially 
for age-related complex diseases this is of increasing interest. Quantification of the 
impact of covariates on the outcome within this type of analysis, however, is still an 
unsolved general problem of epidemiology and statistics. 
The aim of this dissertation was to identify the criterion which suits best for 
quantification of the impact of genetic variants within time-to-onset or survival 
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analysis, similar to a percentage of explained variation in linear regression. Eligible 
criteria were compared in their performance through simulation studies and 
application to mortality data from the KORA studies. 
The introductory chapter of this thesis provides background information on general 
methodology in epidemiology with a focus on study types and survival data analysis. 
Furthermore, the basics of genetics and genetic association studies are described. In 
the main chapter of this thesis (chapter 2), possible criteria for judging the impact of 
genetic variants within survival data analysis are presented and subsequently 
investigated through simulation studies and application to mortality data from a large 
cohort study, the KORA study. The discussion of the results, conclusion and an 
outlook is given in chapter three. 
 
1.2 Epidemiologic studies 
1.2.1 Common study types in epidemiology 
The aim of epidemiologic studies is to describe and investigate diseases and the 
factors influencing them. While clinical studies focus on investigation of treatment 
success, a broad variety of epidemiologic studies aims to identify and describe 
prognostic factors, i.e. factors that influence the probability of occurrence of disease 
or its development. 
To investigate the question of disease development longitudinal or cohort studies are 
the appropriate study design. They start with a baseline investigation and collect 
follow-up information through regular re-examination or questionnaires. Therefore, 
cohort studies offer the possibility to investigate incidence or development of disease 
or health related factors. 
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1.2.2 Terminology 
In the following the disease or health parameter investigated is generally called 
phenotype. Risk factors, i.e. factors that influence this phenotype, are either called 
environmental or genetic factors or covariates. It should be noted that all non-genetic 
factors, including e.g. environmental exposures like fine dust particles, but also life-
style parameters like smoking and even age and sex, are generally termed 
environmental factors. Association analysis quantifies the relation between 
phenotype and environmental and/or genetic factors through statistical analysis. 
Estimated effect sizes describe the relative change in the phenotype due to different 
covariate values. In association analysis, it is common to define a subset of 
environmental or genetic covariates as adjustment covariates beside the covariate of 
primary interest. Adjustment covariates are supposed to influence the phenotype. If 
they also influence the covariate of primary interest, they are called confounders and 
need to be accounted for in analysis. 
 
1.2.3 Statistical methods for analysis of association in 
epidemiologic studies 
1.2.3.1 Methods for cross-sectional and case-control studies 
The statistical model necessary for evaluation of the association between the 
phenotype Y and m environmental and/or genetic covariates X1,…,Xm, depends on the 
distribution of the phenotype. If the phenotype is normally distributed, which is often 
the case in cross-sectional studies, linear regression can be directly applied: 
Y= β0 + β1X1+ β2X2 +…+ βmXm 
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Here, β1,…,βm represent the true effect sizes for each covariate X1,…,Xm, while β0 
gives the baseline level of the phenotype given all covariates are 0. The estimation of 
β1,…,βm is the primary aim of the association analysis. In order to distinguish between 
true and estimated effect sizes, the latter are termed mβββ ˆ,...,ˆ,ˆ 10 and give the relative 
change in the level of the phenotype per unit increase of the covariate.  
Sometimes, however, the phenotype is quantitative but not normally distributed. 
Often, a simple transformation f(Y), then, yields a normalised phenotype and 
replaces Y in the upper regression model. An example would be CRP, a prominent 
inflammatory factor modelled as phenotype in association analysis investigating 
coronary artery diseases, which generally requires a log-transformation to log(CRP) 
and, therefore, yields a so-called loglinear model. 
If the phenotype is a disease indicator, as e.g. in case-control studies, logistic 
regression analysis is performed. The disease indicator is then transformed into a 
probability to develop disease given the observed covariate values. Let the outcome 
Y be the indicator for the observed disease state (1=disease, 0=no disease), X1,…,Xm 
be a set of covariates and β1,…,βm the vector of associated effect sizes. Then the 
logistic regression model with ( )mXXYp ,...,|1 1=  denoting the probability of disease 
given the covariates X1,…,Xm is written: 
( ) ( )
( )
( )mm
mm
mm
m XX
XX
XX
XXYp
βββ
βββ
βββ ++++
+++
=
−−−−+
==
...exp1
...exp
...exp1
1,...,|1
110
110
110
1  
Note that the transformation of probabilities ( )mXXYp ,...,|1 1=  into logits: 
( ) ( )( )






=−
=
=
m
m
m XXYp
XXYpXXYLogit
,...,|11
,...,|1ln,...,|
1
1
1  would yield a linear model. Therefore, 
the logistic model, as well as the loglinear model, falls into the class of generalised 
linear models, where linear regressions are evaluated on the transformed version of 
the phenotype. In logistic regression models, estimated effect sizes βˆ  are often 
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interpreted in their transformed version ( )βˆexp , which are known as odds ratios (OR) 
and act multiplicatively on the probability to get the disease of interest, whereas 
effects on the β scale are interpreted as additive effects on the logits. Odds ratios are 
interpreted as the relative change of odds to get the disease per unit change in the 
respective covariate. 
 
1.2.3.2 Methods for cohort studies 
If the phenotype is measured in a cohort with several repeated measurements at 
each follow-up time point, longitudinal analysis tools including mixed models with 
fixed effects or random effects are applied. The exact model depends on the 
investigator’s focus and possible and necessary assumptions. It is for example 
possible to analyse inter- as well as intra-individual variability or simple changes in 
overall mean values of the phenotype. As longitudinal analysis with repeated 
measurements is a very complex field, which is not the focus of this thesis, no further 
description is given here. 
The second special phenotype available in cohorts with follow-up information is 
called survival phenotype and measures the time until a certain event occurs. Note 
that the name “survival phenotype” originates from mortality data analysis but may 
refer to any time-to-event phenotype, e.g. time to onset of disease (i.e. disease-free 
survival), relapse or surgery. Due to the study design, the event of interest has 
usually not yet occurred for all subjects at follow-up. These subjects with incomplete 
survival times are called censored observations with survival times censored at 
follow-up. An example close to a real study situation is given in Figure 1. Here, 
recruiting of study participants is realised over a period of 3 years. After 4 years, 
follow-up starts. Gathering of follow-up information is here presented to take one 
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year. Nine subjects are still under observation at follow-up. The event of interest has 
not yet occurred. Therefore, they have censored survival times at follow-up while all 
other subjects have complete survival times, where the exact time of the event is 
known. The right panel shows, how individual observation lengths are distributed. 
These are the times modelled in survival analysis. 
Analysis of the time until occurrence of an event, while accounting for this uncertainty 
in the data, requires specialised methodology for analysis. In this case, the outcome 
is not a single variable but a composition between the observed failure time and the 
indicator whether the event of interest has occurred or not (status indicator). The 
methods from survival analysis allow for censoring in the data through definition of 
time dependent risk sets. Therefore, censored individuals are taken into account at 
least as long as they are under observation. 
 
Survival analysis is characterised by three major functions of interest: 
• failure function F(t): cumulated probability to have an event until time t 
• survival function S(t): the probability to not have an event until time t 
• hazard function λ(t): instantaneous probability to have an event at time t+δt, or 
the cumulated hazard as its integral Λ(t) 
 
These three functions are related as follows: 
( ) ( ) ( )( )ttStF Λ−==− exp1  
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Figure 1: A longitudinal study including twenty persons during a recruiting time of three years and a 
follow-up after 4-5 years. Dashed lines mark censored subjects that are still under observation at 
follow-up. Solid lines mark subjects with complete survival times, where the precise time of occurrence 
of the event of interest is known. The left panel shows individual observation times during the study 
period. The right panel shows length of individual observation times. 
 
 
In the following censoring times denote failure times from censored individuals and 
event times are failure times from individuals with an event. In survival analysis, 
estimation is usually performed through non-parametric methods or the semi-
parametric Cox proportional hazards model. As estimation is generally based on risk 
sets and events at event times, individuals with censoring before the first event time 
do not occur in any risk set and can generally be excluded. 
 
Non-parametric survival 
The survival function can be estimated nonparametrically by the Kaplan-Meier 
estimator [Kaplan and Meier, 1958]. For each failure time ti on the time axis the 
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probability of an event is calculated based on the number of events d(ti) relative to 
the number of individuals at risk R(ti): 
( ) ( )( )∏= 






−=
t
oi i
i
KM tR
tdtS 1  
Note that it is usually assumed that the number of distinct time points equals the 
number of individuals. In this case, d(ti) may also be replaced by the individual status 
indicator iδ  which is 0 for censored observations and 1 for observations with an 
event. 
( )tSKM  is often visualised as Kaplan-Meier step function plotted over time with steps 
at each observed event time (e.g. Figure 2 for the example data given in Figure 1). 
Kaplan-Meier curves do not need to end at SKM(t)=0. In Figure 2, for example, 37% of 
the initial population still remain at risk after the last observed event occurred and are 
displayed as censored (cross at the right end of the step function).  Kaplan-Meier 
curves can also be calculated for subgroups which can then be tested for significant 
discrepancies through logrank tests. The nonparametric estimation, however, does 
not allow for adjustment for covariates or analysis of continuous covariates.  
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Figure 2: Kaplan-Meier plot for example data shown in Figure 1. The solid line shows the survival step 
function. Steps only occur at event times. Censored observations are displayed as crosses at 
censoring time points along the step function and contribute to the height of the function as long as 
they are under observation. 
 
Semi-parametric survival (Cox proportional hazards regression) 
In case of continuous covariates or if adjustment for covariates is required, the 
semiparametric Cox proportional hazards model [Cox, 1972] has become standard. 
This model assumes a general baseline hazard ( )t0λ  for all subjects given all 
covariates X are zero, and may be interpreted as a time-dependent baseline risk 
which is shifted for each subject corresponding to its observed covariate values. The 
Cox model is written: 
( ) ( ) ( )XtXt βλλ ′= exp0  
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Constraints on the shape of the baseline hazard through specification of an 
underlying general survival distribution would allow for application of fully parametric 
models. But a priori knowledge is rare and often some distribution, e.g. Weibull or 
exponential, has to be assumed in case of parametric survival analysis. The 
semiparametric Cox model incorporates the baseline hazard ( )t0λ  as a 
nonparametric term without any constraints on its shape except that it accounts for all 
subjects, while all covariates enter the model as parametric terms. 
Estimation in Cox proportional hazards regression is based on the partial likelihood 
function which is the part of the full likelihood that is independent of the underlying 
baseline hazard [Cox, 1975]. It is assumed that censoring is uninformative in the 
sense that censored observations do not contribute additional information to the 
estimation. The logarithm of the partial likelihood is described as:  
( ) ( )∑ ∑ 






−=
≥uncensoredY tt
ii
i ij
XXXPL βββ expln,ln  
Here, it is assumed that the number of distinct failure times k equals the number of 
subjects n and the index i is defined for i=1,…,n. In case of tied failure times (k<n) 
Breslow’s approximation is applied with ∑ ∈= iDj ji XS  and Di the set of indexes with 
equal failure time: 
( ) ( )∑ ∑ 






−=
≥
k
i tt
iii
ij
XdSXPL
01
expln,ln βββ  
The score function ( )XU ,β  resulting from the first derivation of the logarithm of the 
partial likelihood is set to 0 for estimation of effect sizes βˆ . It is written: 
( )
( )
( )∑ ∑
∑










−=
≥
≥
uncensoredY
tt
i
tt
ij
i
i
ij
ij
X
XX
XXU
β
β
β
exp
exp*
,  
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The fraction in this definition may be interpreted as the expectation of the covariate 
calculated over all subjects that are still at risk. 
Effect estimates are interpreted as βˆ  or as hazard ratios, ( )βˆexp=HR , which are 
comparable to odds ratios from logistic regression but have to be assumed to be 
constant over time. This general assumption of constant hazard ratios over time is 
the reason for the full name of the model: Cox proportional hazards regression. 
Proportionality of hazards can be tested based on scaled Schoenfeld residuals 
[Grambsch and Therneau, 1994]. The hazard ratio describes the factor for the hazard 
corresponding to each unit increase in the associated covariate. Like odds ratios in 
logistic regression, hazard ratios act multiplicatively. 
The survival function from Cox regression is defined: 
( ) ( )( ) ( )XCox tXtS 'exp0exp βΛ−=  
It is also possible to visualise the survival function resulting from Cox regression by 
Kaplan-Meier plots. The average survival function is then displayed for all covariates 
taking their mean values. 
 
1.3 Background in genetics 
1.3.1 The human genome 
The genetic information of humans is coded in the form of DNA and stored in the cell 
nuclei. Each nucleus contains 22 pairs of homologous chromosomes, the autosomes, 
as well as two sex chromosomes X and Y, which generally combine as XY in men 
and as XX in women. These chromosomes carry the major part of the genetic 
information. The DNA is a macromolecule composed of four nucleotide bases, which 
are either classified as purines (thymine (T) or adenine (A)) or pyrimidines (guanine 
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(G) or cytosine (C)). Each DNA chain consists of two strands of nucleotide bases that 
are arranged in reverse and complementary fashion. The two strands are connected 
through hydrogen bonds between the complementary base pairs (two bonds 
between purines and three between pyrimidines). DNA is organised into more highly 
coiled structures by folding around histone and other proteins, which play a role in 
gene regulation.  (Figure 3). 
The genetic code is defined by the sequence of nucleotide bases, genes can be 
encoded on either of the two strands. Special strand-specific nucleotide sequences 
encode predefined functions, e.g. start and stop sequences surround DNA 
sequences that encode for transcription areas needed for protein biosynthesis and 
therefore also give the reading direction of a gene  (i.e. a functional sequence in the 
DNA). Protein coding sequences within a gene are called exons, non-coding regions 
within genes and between exons are named introns. Another important region within 
a gene is the promoter, a control point for transcription and therefore substantial for 
regulation of gene expression. 
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Figure 3: Chromosomes are found in each cellular nucleus. The way from chromosome to single base 
pair information is illustrated (Figure from: National Institutes of Health, National Human Genome 
Research Institute, Division of Intramural Research, website:  
http://www.genome.gov//Pages/Hyperion//DIR/VIP/Glossary/Illustration/chromosome.cfm). 
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1.3.2 Single nucleotide polymorphisms 
1.3.2.1 Single nucleotide polymorphisms as genetic markers 
The focus of this dissertation is set on association analysis with single nucleotide 
polymorphisms (SNPs), i.e. single nucleotide exchanges that - by definition of a 
polymorphism - make up at least 1% of the alleles in the population under study. 
SNPs are estimated to describe about 90% of the genetic inter-individual variability 
with respect to single nucleotide exchanges. Therefore, SNPs are of high interest for 
research on complex diseases and health conditions with high prevalence in the 
general population. SNPs from autosomal chromosomes encode the two alleles (i.e. 
nucleotide bases) from the two chromosomes at a specific position in the genome. 
The less frequent allele is called minor allele, the more frequent allele is the common 
allele. SNPs from the male sex chromosome (Y) are special as long as they do not lie 
at the ends of the chromosome which are known as pseudoautosomal regions and 
are similar between X and Y chromosome. The non-pseudoautosomal SNPs only 
encode information from one haploid chromosome, do not recombine in meiosis, 
have thus different properties with respect to formal genetics and are not discussed 
in detail. 
A genotype describes the alleles present for a certain SNP in a single individual. For 
an autosomal or pseudoautosomal SNP a genotype consists of two alleles. 
Genotypes are labeled to be either homozygous, i.e. both chromosomes carry the 
same allele, or heterozygous, i.e. different alleles on the two chromosomes. For 
example, a SNP with the known alleles A and G may yield genotypes AA, AG or GG, 
where AG is the heterozygous genotype. The vast majority of SNPs is biallelic, i.e. 
two different alleles are reported to occur in the specific locus. Nevertheless, it is also 
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possible to have more than two different alleles reported at a specific locus. These 
are considered special cases and require special modeling. 
Large databases with reported SNPs are available. For example, the dbSNP 
(http://www.ncbi.nlm.nih.gov/projects/SNP) to date has registered about 11 million 
SNPs. Until now, about 3.97 Million of these have been validated in the European 
descent population in the course of the HapMap Project 
(http://www.hapmap.org/downloads/index.html.en), which aimed to investigate 
genetic heterogeneity within and between different ethnic groups [Frazer et al., 
2007]. Therefore, it provides additional information e.g. on SNP correlations and 
haplotype patterns in several populations. These and other databases are utilised for 
selection of SNPs for genotyping in genetic association studies. 
The type of possible genetic markers for association analysis, however, is not 
restricted to SNPs. Alternative markers for association analysis include sequence 
repeats in the DNA such as short tandem repeats (e.g. microsatellites) or larger copy 
number variations (formerly termed deletions and insertions)  as well as methylation 
patterns. The variety of genetic markers is growing due to improved knowledge of 
molecular genetics. 
 
1.3.2.2 Genotyping 
Calling of SNP genotypes (genotyping) in a study sample can be performed on 
different platforms. One possibility mainly used for genetic studies with limited 
number of SNPs is to apply primer extensions on parts of each of the two 
chromosomal strands. The length and mass of the extension products then depends 
on the alleles at the specific SNP. Subsequently, genotypes can be determined 
through mass spectroscopy. In this case, genotyping is for example carried out 
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through matrix-assisted laser desorption ionization-time of flight (MALDI-TOF) 
analysis of the obtained primer extension products. Genotyping calls can then be 
made with MassArray RT software (Sequenom, San Diego, USA), where the different 
alleles are visualised through different mass peaks. Details on this technology are 
given in [Vollmert et al., 2007]. 
 
1.3.2.3 Quality control 
Quality control is an important issue in genetic analyses. Before any further analysis 
is performed, the quality of the DNA samples is checked through polymerase chain 
reaction (PCR). Genotyping itself involves further quality checks like double 
genotyping of a predefined percentage of SNPs as well as positive and negative 
controls. Furthermore, the specific structure of sex chromosomes (Y chromosome 
only in men, heterozygous genotypes in X chromosome only in women) allow for 
validation of sex in the database. Random doubles allow for determination of random 
genotyping error which can later be accounted for in analysis [Heid et al., 2008]. 
Person-wise genotyping success rates, i.e. the percentage of successfully genotyped 
SNPs per person, gives additional information on DNA quality. Persons with low 
number of successfully called SNPs are often excluded from further analysis as a 
general problem with the specific DNA sample is indicated. 
The SNP-wise genotyping success rate in a study sample gives information about the 
quality of the genotyping process. Genotyping success rates above 95% are 
generally favourable. Low genotyping success rate may pinpoint to problems during 
the calling process or problematic assay designs. In this case, mainly the number of 
heterozygotes is affected because here, the signals for the two different alleles have 
to be measured whereas homozygotes only yield one signal (see section 1.3.2.2). 
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Therefore, it is also important to control for deviating numbers of heterozygotes. In 
unselected, randomly mating populations the proportion of heterozygotes should 
relate to the proportion of homozygous carriers of the different alleles, with an 
equation called Hardy-Weinberg equilibrium (HWE). Let f(A) be the frequency of 
allele A and f(B)=1-f(A) be the frequency of allele B. Then, the expected genotype 
frequencies are: f(AA)=f(A)², f(BB)=f(B)², f(AB)=2f(A)f(B). It is possible to test for 
HWE given the allele frequencies as well as the observed genotype frequencies 
through Chi² test, or, if the expected number of copies of subjects with any genotype 
falls below 5, Fisher’s exact test. However, if a SNP is supposed to be associated to 
severe diseases that result in early exclusion of specific genotypes, the balance 
between genotypes may be affected in population-based studies (mainly in higher 
age-groups) and thus resulting in HWE violation due to selection. 
Another important measure to control for in association studies is the frequency of 
the minor allele (MAF). Low MAF indicates low power to detect genetic effects, which 
are generally considered to be small for polygenetic diseases. Furthermore, outliers 
in the phenotype variable may become extremely influential in small groups and 
general distributional assumptions for regression models may be violated. Therefore, 
a minimum MAF should be available for SNPs that are examined for association to 
any disease-related outcome. Thresholds for minimum MAF are defined per study 
dependent on sample size and study design. Often a minimum MAF of 1% or 5% is 
required. For example, given a population of 1500 persons, a SNP with MAF=1% 
would yield no more than 10 heterozygotes and 10 homozygous carriers of the minor 
allele under the assumption of perfect HWE. 
In case of multi-SNP analysis, it is also important to check the correlation between 
SNPs. For highly correlated SNPs, the additional information obtained through 
analysis of all SNPs may be small compared to the analysis of a single SNP. For bins 
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of highly correlated SNPs, it may be sufficient to choose one or more representative 
SNPs for analysis of a set of subsequent SNPs. These systematically chosen SNPs 
are called tagging-SNPs [Stram et al., 2003]. 
An overview of further considerations with respect to quality issues and study design 
is given in [Hattersley and McCarthy, 2005]. 
 
1.4 Genetic association studies 
1.4.1 Localisation of phenotype-associated genetic variants 
Localisation of disease-causing genetic variants within the genome is generally a 
stepwise approach. In the first instance, often, general information about heritability 
of diseases is gathered in order to give a first idea of the impact of a genetic 
component on disease development. Especially large, unselected populations are 
more and more in the scope of genetic epidemiological research as they allow best 
for general validity of possible findings. 
Linkage studies may be considered a first traditional step to obtain a rough 
localisation of disease-causing genetic variants as well as the inheritance mode 
through investigation of cosegregation between genetic markers and diseases within 
families [Dawn and Barrett, 2005], [Spielman et al., 1993]. This step, however, 
recently moves more and more into the background. 
Currently, there is increasing interest in association analysis in form of candidate 
gene studies or genome wide screens which allow for direct identification of disease-
related genetic variants [Cordell and Clayton, 2005]. Candidate gene studies focus 
on gene regions that have already been identified as possible carriers of disease-
related genetic variants, e.g. known from the literature, functional analysis or from a 
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positional indication through linkage studies. Genome wide association studies aim at 
screening the whole genome in order to find new regions giving a strong signal of 
association to disease. The possibility to identify completely new areas that play a 
major role in the pathogenesis of disease makes genome-wide association studies 
an important tool. In contrast to candidate gene studies, however, there is often low 
power to find disease-related genetic markers, due to the small expected genetic 
effect sizes (except for monogenic disorders) and the often high number of statistical 
tests that are performed. The growing importance of association analysis for 
identification of genetic variants that indicate increased predisposition to develop 
disease leads to intensified work on related technical as well as methodological 
issues. 
Once having identified genetic variants that are associated to the phenotype of 
interest, further refined studies within the respective gene region follow as well as 
functional studies like gene expression analysis, which validate causality and improve 
insight into the underlying biological mechanisms. An overview over the field of 
genetic epidemiology and research focuses can be found e.g. in [Kaprio, 2000] or 
[Burton et al., 2005]. 
 
1.4.2 Genetic effect models 
1.4.2.1 Genetic effect model definition 
The connection from genotype to the visible phenotype may be closer specified 
through segregation analysis within families. For definition of a model for association 
analysis, a priori information about the inheritance mode and the necessary genetic 
effect model is crucial. Otherwise assumptions have to be made. 
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Genotypes in SNPs are coded by the number of minor alleles observed on the two 
homologous chromosomes. Often, a dose-effect relation between the number of 
copies of the minor allele and the phenotype is assumed. If this relation is linear, the 
genetic effect model is called additive or codominant. If the phenotype has to be 
transformed for statistical analysis, as in loglinear, logistic or survival models, an 
originally additively modelled effect may become multiplicative on the transformed 
scale of the phenotype variable. 
Sometimes, however, no dose effect is visible. In case of a dominant effect model, 
the phenotype is affected as soon as one copy of the minor allele is present but is 
unchanged even if further copies of the minor allele are observed. In case of 
recessive effect models, the phenotype is only affected in presence of two copies of 
the minor allele. 
Nevertheless, it is also possible to avoid constraints on the genetic effect model and 
model the two possible genotypes with at least one minor allele as two single 
indicator variables. The unconstraint model, however, increases the number of 
degrees of freedom used in the statistical tests for association and, therefore, may be 
disadvantageous if, for example, correction for multiple testing is required. 
In case of low frequency of homozygous carriers of the minor allele, which mainly 
occurs for SNPs with low MAF, separate modelling of this group (within unconstraint 
or recessive genetic effect models) is problematic and it may be either excluded or 
similar as in an assumed dominant model, pooled to the group of heterozygotes. 
Due to the high effort of segregation analysis and increasing speed in association 
analysis, a priori knowledge about the genetic effect model is often not available and 
a dose-effect, hence, an additive effect model is assumed. 
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1.4.2.2 Coding of SNP variables 
Coding of the genotypes as variables for statistical analysis depends on the assumed 
genetic effect model. For additive or multiplicative models, the variable has a 
trichotomous design and counts the number of copies of the minor allele. In the 
association model, it enters as a linear term. Dominant or recessive models need the 
genotype coded as dummy variable, which is set to 1 for the genotypes assumed to 
affect the phenotype. The unconstraint model requires two dummy variables, each 
indicating presence of one of the possible variants in the genotype carrying at least 
one copy of the minor allele. 
An interesting variant is the coding of unconstraint genetic effect models through a 
count variable, as under the assumption of an additive effect model, and an extra 
indicator for the group of heterozygotes [Schaid, 2004]. This special coding allows 
clearer insight into the genetic effect model through statistical testing. In case of 
strictly additive effects, the additional indicator for the group of heterozygotes is 
supposed to be not significant. For dominant effects, its estimate is supposed to 
equal the effect obtained for the additive term, whereas for recessive models, it 
should equal the additive term’s effect estimate with reversed sign. 
 
1.4.3 Methods to quantify the genetic effect 
1.4.3.1 Estimation of genetic effect sizes 
Estimation of genetic effect sizes depends on the distribution of the phenotype and 
the necessary regression model for association analysis (see section 1.2.3). 
In linear regression, the genetic variants are entered into the model corresponding to 
the chosen genetic effect model either as single covariates or as a set of covariates. 
Additional adjustment for environmental covariates and confounders is possible. 
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However, it is recommended to investigate models with and models without 
adjustment for additional covariates. In some cases, it may even be favourable to 
consider different adjusted models in order to better specify side or confounder 
effects. 
Estimated effect sizes are interpreted as relative changes in the phenotype obtained 
for the variant compared to the reference. In additive, dominant or unconstraint 
genetic effect models, the reference is the group of homozygous carriers of the 
common allele. For recessive effect models, the reference also includes the 
heterozygotes. For additive models, the estimated effect size is interpreted as 
change in the phenotype per copy of the minor allele. 
P-values for judgement of significance of the estimated effect sizes βˆ  are usually 
obtained through statistical tests like t-tests or Wald tests on the null 
hypothesis 0ˆ =β . Like in general epidemiologic studies, p-values below 5% are 
usually considered significant for single SNP analysis. In multi-SNP analysis or 
different models including different adjustment for environmental covariates, 
correction for multiple testing may be necessary to guarantee the overall significance 
level of 5%. 
 
1.4.3.2 Quantification of the impact of genetic variants 
In genetic association studies, it is of growing interest to report more than estimators 
of genetic effect size and p-values in order to allow for further specification of the 
impact of genetic variants on disease outcome. This is particularly an issue in studies 
based on population representative cohorts without special ascertainment criteria 
(such as e.g. extreme phenotype selection). For quantification of the impact of 
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genetic variants, a general focus is set on quantitative criteria that allow for model 
comparison and model selection. 
Likelihood-based criteria like Akaike’s information criterion (AIC) or likelihood ratio 
tests are often the basis of model selection. The values themselves, however, are 
difficult to interpret and do not allow the quantification of the impact of covariates on 
the outcome. Measures of discrimination quantify the predictive capability of a model 
if the association analysis is seen as a classification problem. Therefore, they may be 
suitable within a logistic regression framework or classification and regression trees 
(CART). However, measures of discrimination like AUC (area under the receiver 
operator characteristic curve) tend to ignore the associated effect size [Cook, 2007] 
which should also contribute to a general measure of impact. In the case of 
continuous outcomes, measures of discrimination would furthermore lead to a loss of 
information due to the reduction of the analysis to a classification problem. Therefore, 
variation-based measures such as the explained variation, obtained as R² in linear 
regression, are generally more attractive to measure the impact of genetic variants. 
In the following, possible definitions of R² are given for linear and generalised linear 
regression. 
 
R² in linear regression 
For linear regression models, the estimation of the explained variation or predictive 
accuracy is obtained through calculation of the coefficient of determination, R² 
[Rosthoj and Keiding, 2004]. This coefficient may be interpreted as the squared 
correlation coefficient as well as on basis of sums of squares or variance 
components. The definition of R² based on sums of squares is as follows: 
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2ˆ  be the sum of squared error or residuals, i.e. 
discrepancy between observed outcomes iy  and their expectation iyˆ  given the 
model is true. Then, R² is calculated as: 
SST
SSER −= 12  
A discussion of possible alternative formulations is given in [Kvalseth, 1985]. It is also 
possible to correct R² for the number of predictor variables through introduction of a 
shrinkage term [Van Houwelingen and Le Cessie, 1990]. 
 
R² in generalised linear  regression  
For models other than the linear model, the appropriate definition of R² is less clear, 
which is often due to missing residual definitions. And the proper choice becomes a 
challenging task [Kvalseth, 1985]. A widely accepted definition of R² is the general 
coefficient of determination for generalised linear models which is calculated based 
on the likelihood of a model [Nagelkerke, 1991] and is often implemented in standard 
software packages. Let ( )0L  be the log-likelihood of the null model and ( )βˆL  be the 
log-likelihood of the fitted model for the sample of size n. Then R² as defined by 
Nagelkerke is calculated as follows: 
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However, this general definition suffers in case of discrete distributions, e.g. in logistic 
regression models. In these models, the maximum attainable value may be below 0. 
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The maximum attainable value 2maxR  is calculated through setting ( ) 1ˆ =βL . Division of 
2
NR  by 
2
maxR leads to the adjusted coefficient 2
max
2
2
R
R
R Nadj = , which is often also returned 
by standard software. 
 
 2. Impact of genetic variants on survival phenotypes 26 
 
2 Impact of genetic variants on survival phenotypes 
2.1 Aim of the study 
2.1.1 Genetic association analysis with survival phenotypes 
The link between genetics, epidemiology and statistics is a currently fastly developing 
field. In genetics, studies were initially mainly performed within families. Later, the 
field of genetic research was extended to include case-control studies. The 
breakthrough of population-based genetics started with genotyping and evaluation of 
large cross-sectional studies and prospective cohort studies. There is more and more 
extensive long-term follow-up data available for large cohorts, which allow analysis of 
longitudinal development of diseases, incidence and survival. In statistics, new 
methods for analysis of family data and analysis of large scale genetic data had to be 
developed. Existing methods for analysis of cohorts (i.e. longitudinal data or survival 
data) had to be extended for application in genetic epidemiology. Hence, for each 
new setting, the link between the three involved research areas (genetics, 
epidemiology and statistics) had to be created and knowledge had to be transferred 
and combined. Therefore, genetic epidemiology can be seen as a strongly 
multidisciplinary field of research. A list of currently available statistical methods for 
genetic association studies with different epidemiologic study designs can be found 
in [Cordell and Clayton, 2005]. 
Statistical methods from the survival framework allow analysing the association 
between early onset or occurrence of diseases, e.g. type 2 diabetes or myocardial 
infarction, or death and genetic variants. Especially for type 2 diabetes, the current 
worldwide epidemic [Wild et al., 2004] invoked intensified research in the field of 
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genetic epidemiology - with the aim to identify genetic variants that may be one 
reason for the increased spread of the disease. Since, the link between genetic 
epidemiology and survival analysis has been established, it is possible to not only 
analyse genetic effects on incidence through methods for case-control studies. 
Moreover, it is now possible to analyse genetic effects on the time of disease onset 
through definition of (disease-free) survival phenotypes as combination of: 
1) a time variable (time of disease onset, if the disease occurred, or last time of 
follow-up, if the disease has not occurred until the last follow-up) 
2) a status indicator (indicator whether the disease occurred) 
The link between survival analysis, as a specialised field of statistics, and genetic 
research is still young and adaptation of specialised statistical methodology to the 
new fields is still ongoing. 
 
2.1.2 Measures of the impact of genetic variants on survival 
phenotypes 
It is of increasing interest not only to assess existence of association, but also to 
quantify the impact of a genetic variant on phenotypes through measures of 
explained variation. As described in section 1.4.3.2, criteria measuring explained 
variation exist for quantitative phenotypes that are normally distributed (R²) or for 
phenotypes analysed through generalised linear regression, e.g. dichotomous 
outcome in case-control data, (R²N or R²adj).  
Standard analysis through Cox regression yields the usual measures of association 
between genetic variants and time of diagnosis (or death): Hazard ratios and p-
values help quantifying the strength of the association between genetic variant and 
survival phenotype. Measuring the impact of genetic variants on survival phenotypes 
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by means of a criterion comparable to R², however, is not yet possible, as a generally 
recommended criterion measuring explained variation for survival data is still missing. 
Currently, a number of possible solutions addressing this topic exist (a selection is 
presented in section 2.1.4.1). However, no systematic investigation with a particular 
focus on possible application for genetic association studies has been conducted, 
yet. 
 
2.1.3 Aim of this thesis 
As survival outcomes are a composition of the two variables observation time and 
event indicator, no clear residual definition is available for survival analysis. 
Therefore, the definition of a criterion of predictive accuracy or of explained variation 
of a model, similar to R² in linear regression, currently leads to a variety of answers. 
Research within this topic faces a long history and is still ongoing. New methods are 
developed and existing possible solutions are permanently extended and improved. 
Therefore, no clear general recommendation is available, yet. 
The aim of this thesis was to identify the optimal criterion for judging the impact of 
genetic variants on survival phenotypes. The literature was searched for criteria 
suitable to quantify the contribution of a trichotomous or dichotomous variable (as for 
SNP data) to survival phenotypes (survival or disease-free survival data). Eligible 
criteria should have an interpretation close to R² in linear regression models and fulfil 
the following characteristics: 
(a) reasonable criteria values in the range [0;1] in order to allow for interpretation 
as percentage of prediction quality 
(b) increasing values with increasing effect size 
(c) independence of the percentage of censored observations in the data 
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Identified eligible criteria were tested for their suitability to quantify the impact of SNP 
genotypes on survival phenotypes through simulation studies. Simulation scenarios 
were aimed to cover realistic situations (regarding MAF, genetic effect size, genetic 
effect model, censoring percentage and censoring mechanism) as well as extreme 
settings in order to investigate the range of criteria values and their dependence on 
the varied parameters. 
Furthermore, we aimed to illustrate the performance of the criteria for real data 
situations. Therefore, the criteria were applied to association analysis for SNPs and 
survival data from the KORA (Kooperative Gesundheitsforschung in der Region 
Augsburg) survey S3 from the region of Augsburg, South Germany, including its ten-
year follow-up (F3). Genotyped SNPs from genes that are considered as potential 
candidates for association to outcomes related to severe diseases, such as type 2 
diabetes or dyslipidemia were available for analysis. Severe diseases like type 2 
diabetes and related markers are known to be associated to comorbidity and 
mortality [Bell et al., 2005],[Capri et al., 2006]. Therefore, we aimed to analyse these 
SNPs for association to survival and to elucidate the performance of the criteria to 
quantify the impact of SNP genotypes on survival phenotypes. 
 
2.1.4 Literature search 
2.1.4.1 Overview of available criteria 
A general idea about the structure of criteria measuring the impact of covariates has 
been given in section 1.4.3.2. Criteria measuring the impact of covariates can 
generally be divided into three main categories: 
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1) likelihood-based criteria 
2) measures of discrimination 
3) variance-based criteria 
 
For survival data analysis, a comparison of eight criteria from these three fields, that 
were at least discussed until 1994, is given in [Schemper and Stare, 1996]. More 
were invented and improved later. Some criteria investigated during literature search 
are mentioned in Table I. Some of which, like the variance-based criteria, already 
face a long history of development and improvement. Two criteria, D and the Brier 
Score, are difficult to categorise into one of the upper groups. Their structure is 
variance-based but originates from a discrimination point of view. 
 
Table I: A selection of criteria proposed for judging the impact of genetic variants. 
Characterisation Criterion Reference 
Likelihood-based criteria: AIC or BIC e.g. [Harrell, Jr., 2001] 
 R²LR [Maddala G.S., 1983],  
[Magee, 1990] 
 R²N [Nagelkerke, 1991] 
 ρ²W,A or ρ²PM [Kent and O'Quigley, 1988] 
Measures of discrimination:  AUC e.g. [Harrell, Jr., 2001] 
 Somer’s DXY [Somers, 1962] 
 Harrell’s C [Harrell, Jr. et al., 1982] 
 D1 or SEP [Sauerbrei et al., 1997] 
Variance-based measure of 
discrimination: 
D [Royston and Sauerbrei, 2004] 
 Brier Score [Graf et al., 1999] 
Variance-based criteria: kd.norm [Stark, 1997] 
 V and Vw [Schemper and Henderson, 2000] 
 R²sch [O'Quigley and Xu, 2001] 
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2.1.4.2 Criteria selection  
As described in section 1.4.3.2, the general focus was set on measures of predictive 
accuracy or explained variation, hence, variation-based criteria. Likelihood-based 
criteria are often difficult in interpretation or need to account for additional correction 
factors (see e.g. section 1.4.3.2). Measures of discrimination are not eligible for non-
categorical phenotypes. The literature search yielded three variance-based criteria: 
kd.norm [Stark, 1997], V [Schemper and Henderson, 2000], and R²sch, defined as R² 
based on Schoenfeld residuals [O'Quigley and Xu, 2001]. These three criteria that 
have been proposed for quantification of the contribution of covariates to survival 
phenotypes allow for interpretation as percentage. They are described in detail below 
(section 2.2.1). All three criteria incorporate the estimated effect size βˆ  from the Cox 
model, without or with adjustment for additional covariates. The two criteria, D and 
the Brier Score, are each closely related to one of the criteria chosen for closer 
investigation in simulation studies: A direct correspondence between the Brier Score 
and V has been shown, and D is closely related to kd.norm. 
 
2.2 Methods 
2.2.1 The three selected criteria 
2.2.1.1 Criterion based on cumulated hazard (kd.norm) 
The first criterion is based on deviance residuals, which are derived from martingale 
residuals. Martingale residuals are defined per individual i as the difference between 
the observed survival status, given by the status indicator δi=I[individual i has an 
event], and the cumulative hazard at the observed time ti [Therneau et al., 
1990]: ( )iii tM Λ−= δ , for i=1,…, n subjects. Martingale residuals may be applied to 
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investigate the functional form of covariates [Therneau et al., 1990]. However, they 
have a highly skewed distribution and are not suitable for definition of a performance 
criterion like a measure of explained variation. 
The following transformation of Martingale residuals yields the deviance residuals, 
which may also be interpreted as contributions to the deviance of the model: 
( ) ( )( )iiiiii MMMresdev −+−= δδ ln2sgn.  
Square root and logarithm, here, result in a more normalised distribution of deviance 
residuals, compared to Martingale residuals. For the definition of a criterion of 
prognostic value, it has been proposed to apply an absolute loss function on 
deviance residuals to measure the difference between null model and covariate 
model. With dev.resi being the residual from the null model and dev.resi|X the residual 
from the covariate model, the criterion kd.norm, according to [Stark, 1997], is written as 
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As kd.norm incorporates the full vector of estimated effect sizes βˆ  from the Cox model 
in the above stated cumulative hazard function ( )itΛ  when computing iM , this 
criterion measures the impact of the full set of covariates in the case of more than 
one covariate in the model. 
 
2.2.1.2 Criteria based on variation of individual survival curves (V and Vw) 
The second criterion is based on measuring the weighted difference in the variation 
of the individual survival curves [Schemper and Henderson, 2000], for which a direct 
correspondence to the Brier score was shown [Gerds and Schumacher, 2006]. The 
variation of individual survival curves dependent on time t is defined as S(t)(1-S(t)). A 
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criterion of relative gain is then formulated as the relative difference of the integrated 
and weighted variance over the complete observation time [0;τ] between its 
expectation ( ) ( ){ }[ ]XtSXtSE X −1  in the covariate model and the null model. 
Introduction of weighting function f(t) leads to the definition of criterion V: 
( )
( ) ( ){ } ( ) ( ) ( ){ }[ ] ( )
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The complete estimation equation can be found in [Schemper and Henderson, 2000]. 
The weighting function f(t) is introduced to reduce dependence on censoring in the 
data and incorporates the “reverse Kaplan-Meier estimator” [Schemper and Smith, 
1996], [Altman et al., 1995]. Note that estimation is only performed for event time 
points 1=itδ . 
A slight modification of V, denoted as Vw, is obtained if the order of the operations is 
exchanged, i.e. if the integration is performed for weighted relative differences in 
variances: 
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Again, as V and Vw involve the full vector of estimated effect sizes βˆ  from the Cox 
model in the above stated survival function ( )tS , these criteria measure the impact of 
the full set of covariates in the case of more than one covariate in the model. 
 
 2. Impact of genetic variants on survival phenotypes 34 
 
2.2.1.3 Criterion based on variation of Schoenfeld residuals (R²sch) 
The third criterion is based on Schoenfeld residuals [Schoenfeld, 1982], which are 
the summands of the score function derived from the partial likelihood. These 
residuals measure the difference between the observed covariate values at event 
times 1=itδ  and their expectations given the estimated βˆ  from the Cox model. Hence, 
Schoenfeld residuals are defined per covariate Xk as a vector over event time points 
1=i
tδ : 
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As in the context of linear models, a criterion similar to ordinary R² can be defined 
based on squared residuals at event times [O'Quigley and Flandre, 1994]. For the 
calculation of the necessary null model residuals, covariate values are expected not 
to be associated with time and are randomly assigned over event time points 
dependent on the survival distribution. This becomes clear by setting 0ˆ =β  in the 
upper residual definition. In case of tied failure times, residuals can be split randomly 
between the observations. 
For more than one covariate, the Schoenfeld residual definition can be extended to 
measure differences in the prognostic index Xβη ˆ ′=  instead of differences in a single 
covariate [Andersen et al., 1983]. The residual for the prognostic index is therefore 
the linear combination ( )1,ˆˆ =′ itres δββ . Furthermore, introduction of weights ( )1=itw δ , 
defined as the difference in step height of the marginal Kaplan-Meier curve at times 
1=i
tδ , reduces dependence on censoring. The criterion R²sch defined by [O'Quigley 
and Xu, 2001] is then written as: 
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Therefore, the Schoenfeld residuals allow for both measuring a single covariate’s 
impact while adjusting for other covariates as well as measuring the impact of a full 
set of covariates.  
 
2.2.2 Simulation studies 
In order to evaluate these criteria with respect to their performance in genetic 
association studies, simulation studies were performed for biallelic single SNPs. 
Different scenarios were defined through different genetic effect models, minor allele 
frequencies (MAF) of SNPs under the assumption of Hardy-Weinberg equilibrium 
(HWE) and different effect sizes, as well as failure times created for varying 
censoring percentage and type of censoring mechanism. For each scenario, 200 
datasets each consisting of n=1000 observations were simulated. 
2.2.2.1 Simulation of genetic variants 
In order to create situations comparable to SNP association studies, SNP genotype 
data were generated as random variables X∈{0, 1, 2} with X representing the 
number of copies of the minor allele. Probabilities for X, which correspond to the 
genotype frequencies (π0, π1, π2), were calculated under the assumption of perfect 
HWE for MAF of 5%, 10%, 25% and 50% as π0=(1-MAF)², π1=2*MAF*(1-MAF) and 
π2=MAF². 
Variance-based criteria, e.g. R² in linear regression, also depend on the variance 
of the covariate. The assumption of perfect HWE restricts the variance of the genetic 
covariate. Therefore, additional simulations were performed for situations with 
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violation of HWE with genotype frequencies (π0, π1, π2) set to (0.6, 0.3, 0.1) (i.e. 
MAF=25%), (0.3, 0.4, 0.3) (i.e. MAF=50%) and (0.2, 0.7, 0.1.) (i.e. MAF=45%). 
These genotype frequencies yielded p-values below 10-9 for Fisher’s exact test for 
HWE. 
Simulations were performed for additive, dominant and recessive genetic effect 
models with corresponding coding of the genetic covariate. The HR for the 
association of the genetic variant was varied as ∈HR {1.25, 1.5, 2, 4, 8}. Especially 
genetic effect sizes between 1 and 2 are expected to be realistic effect sizes in SNP 
analysis of complex diseases, whereas higher effect sizes may occur for major genes 
or in extreme settings. For exploring limitation behaviours of the three criteria, also a 
hazard ratio of HR=128 was simulated, which is a very extreme effect size and most 
unrealistic. 
 
2.2.2.2 Simulation of survival outcome 
Simulation of survival outcomes as combination of failure time and status indicator 
required generation of two random variables for each individual i, i=1,…,n: one event 
time and one for censoring time. Event times Ti were generated as exponentially 
distributed random variables according to [Bender et al., 2005]. The generation of 
censoring times Ci depended on the chosen censoring mechanism as described 
below. The final failure time ti and the survival status indicator δi per individual were 
then calculated as ti=min(Ti, Ci) and δi=I[Ti≤Ci]. 
 
2.2.2.3 Simulation of censoring times 
Censoring was chosen to imitate two common study designs: Setting 1 (fixed 
censoring): All individuals enter the study at the same time and general censoring is 
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applied at time τ. Hence, time of censoring is constantly C=τ for all individuals i. This 
corresponds e.g. to cross-sectional surveys including follow-up. Setting 2 (random 
censoring): Individuals enter the study continuously over time until general censoring 
is introduced at time τ. In this setting, the time of censoring is a uniformly distributed 
random variable C~Unif[0,τ]. This situation with ongoing recruiting is often found in 
clinical studies. For each scenario, values of τ were varied to obtain censoring 
percentages of 10%, 25%, 50%, 80%, and 90%. 
 
2.2.2.4 Extended simulation scenarios with continuous covariates 
In genetic association analyses, it is often necessary to also include environmental 
covariates which follow a continuous distribution. Therefore, the performance of the 
presented criteria was also evaluated for continuous covariate distributions. Chosen 
covariate distributions were as follows: 
1) a standard normal distribution: X~N(0;1)  
2) a standard uniform distribution: X~Unif[0;1] 
3) a normal distribution with variance 1/12: X~N(0;1/12) 
 
These distributions were chosen for the following reasons: 
1) Represents a standard covariate in epidemiologic studies. 
2) May be a covariate that is also included in the study design. Study 
participants, for example, are often chosen uniformly distributed over age. 
3) Has equal variance as 2 and has been added for comparison between normal 
and uniform distribution. 
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The assumed hazard ratios in these settings were similar to the simulations with 
trichotomous SNP covariates with hazard ratios set to 1.25, 1.5, 2, 4, and 8. 
However, it was necessary to reduce the extreme hazard ratio from the genetic 
settings (HR=128) to HR=32 in order to guarantee convergence of the model 
estimation. 
 
2.2.2.5 Bivariate simulations with genetic variants and a continuous covariate 
Finally, to mimic a more realistic situation where a quantitative prognostic factor 
explains a substantial proportion of the survival outcome, simulation scenarios 
combining genetic and quantitative variables were created. Here, a standard normally 
distributed covariate X~N(0;1) was simulated with log(HR)=1, thus a HR of 2.72, 
additional to the genetic variant as described before (see section 2.2.2.1). 
 
2.2.2.6 Statistical analysis and simulation summary 
For each dataset in the SNP simulations, the effect estimates βˆ  of the SNP from 
fitting a Cox-model and the criteria kd.norm, V and R²sch were calculated under the 
assumption of an additive, dominant or a recessive genetic effect model. The 
criterion Vw, as a possible alternative to V, was also calculated, but is not in the focus 
of this thesis as it is very similar to V. 
The additional settings for SNPs violating the HWE assumption were analysed only 
for additive effects because deviations from HWE are mainly visible in trichotomous 
coding of the SNP covariate. 
For each dataset in the simulations with a continuously distributed covariate, the 
corresponding estimates of log(HR) per unit increase were estimated. For the 
simulation scenarios combining both a genetic and a quantitative variable, the Cox 
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model included both the SNP genotype and the quantitative variable. The criteria 
values then depict the combined impact of both. For each simulation scenario, mean 
and standard deviation of the effect estimates and each criterion were computed 
across the 200 simulations. 
Simulated datasets where the Cox proportional hazards model showed convergence 
problems were discarded and replaced in order to guarantee an overall number of 
200 evaluated datasets. Convergence problems occurred mainly in case of almost 
monomorphic behaviour of the genetic variable in the event group (δi=1). Therefore, 
mainly recessive models for SNPs with low MAF were affected and recessive models 
were only generated for minor allele frequencies of 25% and 50%. 
All simulations and statistical analysis were performed with the R software version 
2.4.1[R Development Core Team, 2007]. 
 
2.2.3 Real data analysis 
2.2.3.1 The KORA data S3/F3 for survival analysis 
The KORA (Kooperative Gesundheitsforschung in der Region Augsburg) study 
divides into four baseline surveys conducted in the years 1984/85 (S1), 1989/90 (S2), 
1994/95 (S3) and 1999/2001 (S4). These surveys have been conducted as 
population-based samples stratified by age and sex drawn from the local registries. 
The study region comprises Augsburg and its two surrounding counties. Study 
participants were invited to undergo medical examination in the KORA study centre. 
Persons who did not want to participate were asked to answer a non-responder 
questionnaire. Follow-up information in surveys S1-S3 was gathered through two 
postal questionnaires (GEFU1 and GEFU2) in the years 1997/98 and 2002/03. 
Indication of disease in these short questionnaires required validation through the 
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attending physician and written consent of the study participant. In case of death, the 
exact date of death was confirmed through death certificates from the local health 
departments. Therefore, exact dates of death or first diagnosis of disease, e.g. 
myocardial infarction, coronary heart disease or type 2 diabetes, are available for 
analysis within survival framework. 
Furthermore, thorough 10-year-follow-up data are available for participants in KORA 
S3, who were invited to the KORA study centre for re-examination in the years 2004-
2006. Therefore, more phenotypes are available for this follow-up than for GEFU 
data. More details on KORA as a research platform for health research can be found 
in [Holle et al., 2005]. 
Mortality data to apply the selected criteria were obtained from the KORA study S3. 
Mortality follow-up after 10 years and DNA samples were available for 4420 study 
participants as well as information on sex and age. A short description of the data 
available for analysis is given in Table II. 
 
Table II: Description of the KORA S3-F3 data available for mortality analysis 
Sample size 4420 
Men 50.4% 
Average age at baseline (S3) 49.5 years 
Mortality 7.6% 
Median follow-up of all survivors 3549 days 
 
 
In total, 51 autosomal SNPs from different genes with possible or known associations 
with severe diseases or related parameters such as diabetes, myocardial infarction or 
dyslipidemia were chosen. As these diseases and related conditions are supposed to 
be related to mortality, it was hypothesised that some of these SNPs would be 
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associated with mortality. Genotyping had been performed using MALDI-TOF MS 
technology. Because association with mortality could affect the genotype distribution 
in the higher age group violation of HWE is a possible indicator for association to 
mortality. Therefore, deviations from HWE were tested by the exact HWE test 
described by [Emigh, 1980], but did not result in exclusion from analysis of the 
particular SNP. 
 
2.2.3.2 Adding simulation of SNPs associated with mortality 
As no strong association with mortality was expected for the investigated real SNPs, 
artificial SNPs with minor allele frequency of 25%, perfect HWE and three different 
magnitudes of additive genetic effect on the β level (i.e. multiplicative effect on 
hazard ratio scale) on mortality were created as follows: 
First, genotypes of an initial artificial SNP were assigned to individuals based on the 
percentiles of ordered failure times from the KORA data. Percentiles were chosen 
corresponding to the genotype frequencies (i.e. for MAF=25%: π0=56.25%, 
π1=37.5%, π2=6.25%). Homozygous carriers of the minor allele were chosen to be at 
the highest risk for death. Therefore, genotype value 2 was assigned to the 6.25% 
shortest survival times and genotype value 0 was assigned to the 56.25% longest 
survival times. No association of genotypes with other covariates was assumed. 
Given the high censoring percentage in the KORA data, this design, would have lead 
to an almost complete separation of cases from the group of genotype 0. This would 
have resulted in convergence problems for estimation of the association, especially 
for a dominant model. Therefore, a small random error was added on each genotype 
group. Variation of the percentage of randomly assigned genotypes from the original 
artificial SNP yielded SNPs with different degrees of association to mortality: 
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• To obtain strongest association to mortality, an “extreme SNP” was generated 
through random assignment of genotypes with probability of 2% to the 
genotype carrying one minor allele more or less than the original genotype. 
• A “strong SNP” with lower but still strong association to mortality was obtained 
through random assignment of 25% of genotypes to any genotype with 
probabilities corresponding to the original genotype frequencies.  
• A “moderate SNP” with moderate association to mortality was created the 
same way as the “strong SNP” but through random assignment of 50% of the 
original genotypes. 
Note that the chosen simulation approach keeps MAF=25% for all artificial SNPs. 
 
2.2.3.3 Statistical analysis and the impact of the genetic variants 
In real data analysis, the Cox model was fitted for time since baseline survey S3. 
Each of the SNPs (51 real SNPs and three artificial lethal SNPs) was analysed 
unadjusted as well as adjusted for age and sex and values for kd.norm, V and R²sch 
were calculated. Note that criteria values in the adjusted models depict the combined 
impact of SNP, age and sex. 
As genotype distributions of SNPs with association to mortality are supposed to affect 
longevity, it is possible that dependence on age is already visible at baseline. 
Therefore, further investigation was conducted for real data SNPs: 
1. In order to investigate whether any dependence of genotype distributions on 
age exists in real SNPs, linear models adjusted for sex were fitted against age 
at baseline.  
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2. Another Cox model was added for the real data SNPs with the time variable 
defined as age at death and adjustment for sex. This model was supposed to 
better account for this possible situation. 
The significance level corrected for multiple testing was obtained according to 
Bonferroni as the significance level of 5% divided by the number of models multiplied 
by the number of independent marker loci. The latter was calculated through spectral 
decomposition of the SNP correlation matrix as described by [Li and Ji, 2005]. 
 
2.3 Results 
2.3.1 Results from SNP simulation studies 
2.3.1.1 Overview 
As described in section 2.1.3, comparison of the performance of the selected criteria 
in genetic association analysis with survival phenotype was conducted for simulated 
data with different scenarios (varying MAF, genetic effect size, genetic effect model, 
censoring percentage and censoring mechanism). Evaluation of the three 
investigated criteria focused on the following items: 
(a) reasonable values in the range [0;1] 
(b) increasing values with increasing effect size.  
(c) independence of censoring 
Each of these items required inspections from several points of view and direct as 
well as indirect links were discovered. In the following, results are presented 
corresponding to the upper main items a, b and c. 
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Throughout the investigation, criterion Vw yielded values very close to those of V - 
with a tendency to be slightly smaller. Therefore, results for Vw are not presented in 
detail in the following. 
 
2.3.1.2 Reasonable values in the range [0;1] 
Observed range of criteria values 
As a demand of interpretability as percentage of maximum possible impact on the 
phenotype, criteria values should range between 0 and 1, with 0 denoting no impact 
and 1 denoting 100% impact on the survival phenotype. In all SNP simulation 
scenarios, the mean values of all investigated criteria were limited to the interval 
[0;1]. V, however, did not cover the full range. Simulation results are presented in 
Figure 4 for the case of a SNP with MAF=25% under the assumption of fixed 
censoring.  
V yielded generally low values and did not reach unity even for the most extreme 
scenario. For example, for the data presented in Figure 4, even for the highest effect 
size of HR=128, V hardly exceeded 60-65%, while R² and kd.norm approached 100%. 
For the lowest effect size HR=1.25, values close to zero were obtained for V and 
R²sch and values up to 10-15% for kd.norm. 
For single simulated datasets with low effect size, V and R²sch yielded slightly 
negative values (>-0.01). This cannot be seen from Figure 4 as the mean values over 
the 200 simulated datasets were positive. Values below 0 indicate a better fit of the 
null model than the covariate model, which may occur in cases of low association. 
As, for both criteria, mean values are positive, single values slightly below 0 may be 
interpreted as “no impact”. 
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Dependence on genotype variance 
Criteria like R² in linear regression measure the reduction of variance in the 
phenotype due to the covariates in the model. Therefore, they also depend on the 
variance of the covariates. 
For genetic variants, the variance of the genotype covariate X depends on the 
genotype frequencies and the assumed genetic effect model. The variance for 
qualitative covariates X is generally defined as: 
( )∑ −
=
=
n
i
xxinX 1
21)var( , with n=sample size and x denoting the mean value of X 
 
 2. Impact of genetic variants on survival phenotypes 46 
 
 
Figure 4: Survival data with fixed censoring were simulated for a single covariate { }2;1;0∈X  with 
sampling probabilities calculated from MAF=25%. Mean values of the investigated criteria judging the 
impact of the single genetic covariate (a) for additive and (b) dominant and (c) recessive effect models 
are plotted against hazard ratios (HR). For each value of HR, results for different censoring 
percentages (cens) are presented as different point characters (adding small scatter on the x-axis for 
differentiation). The range of standard deviations (std) averaged over the 200 simulated data sets per 
scenario is given in each panel. 
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For genotype data x = 2*MAF, and, for trichotomous coding of the genotypes, the 
sum is calculated over genotypes. With n0, n1 and n2 denoting the genotype counts, 
the upper formula, therefore, reduces as follows: 
( ) ( ) ( ) ( )222120 *22*21*2var MAF
n
nMAF
n
nMAF
n
n
X −+−+=  
The fractions, then, represent the genotype frequencies. 
In case of perfect HWE (as in the majority of the chosen simulation scenarios), all 
genotype frequencies can directly be calculated from the MAF and the formula for the 
genotype variance can be directly calculated from this single parameter: 
( ) ( ) ( ) ( ) ( )222 *22**21)1(**2*2*1var MAFMAFMAFMAFMAFMAFMAFX −+−−+−=
 
For dichotomous coding of SNPs, as in recessive or dominant genetic effect models, 
calculation of the variance is based on the formula for binomial data: 
( ) 




 −=
n
nnX 11 1*var  , with n1 denoting the number of observations with X=1 
As n1 either equals the sum of observed numbers of genotypes 1 and 2 (dominant 
model) or the number of genotypes 2 (recessive model), the derivation of the 
variance, again, is directly related to the MAF and therefore straightforward. 
The variances calculated for the genetic covariates in the chosen simulation settings 
are shown in Table III. 
The simulations revealed that all criteria increase with increasing MAF (assuming 
HWE) or, more generally speaking, increasing genotypic variance (independent of 
HWE assumption). 
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Table III: Genotype frequencies, MAF and variance of the genetic covariate in the chosen genetic 
simulation settings are shown. 
  Variance of genetic covariate 
Genotype frequencies 
for genotypes (0;1;2) MAF 
Additive 
effect model 
Dominant 
effect model 
Recessive 
effect model 
90.25%, 9.5%, 0.25% 5% 9.68% 8.85% --- 
81%, 18%, 1% 10% 18.02% 15.41% --- 
56.25%, 37.5%, 6.25% 25% 37.45% 24.64% 5.82% 
25%, 50%, 25% 50% 50.05% 18.77% 18.77% 
60%, 30%, 10%* 25% 45.05% --- --- 
20%, 40%, 30%* 50% 60.06% --- --- 
20%, 70%, 10%* 45% 29.03% --- --- 
* SNP violating HWE with p<10-9; simulations were only performed for the additive effect model 
 
In Figure 5, this dependence is shown for the additive effect models. Dominant and 
recessive effect models have been excluded from Figure 5 due to the different 
scaling of the genetic covariate. In order to exclude any effects resulting from 
dependence on censoring, Figure 5 is only displayed for settings without censoring. 
Highest criteria values were observed for SNPs with genotype frequencies set to 
(0.3; 0.4; 0.3), which is the setting that is close to an equally balanced design and 
therefore highest variance in the trichotomous SNP covariate. The relation between 
the criteria values and the variance of the genotypic covariate was found as an 
almost linear trend. The general dependence on the covariate’s variance is also 
verified in the additional simulations for continuous covariate distributions, as 
described later.  
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Figure 5: Average values of criteria are plotted for all additive effect models included in simulations 
with HR=4 and without censoring against the calculated variance of the genotypic covariate. 
 
Summary of results: limitation behaviour 
For all of the investigated criteria, the limitation to the range [0; 1], which is necessary 
for interpretation as percentage of explained variation, is fulfilled in the SNP 
simulation scenarios. A general increase with increasing genotype variance has been 
observed, which is in line with the expected characteristics of variance-based criteria. 
In case of very small effects, Kd.norm and R²sch yield values close to zero and approach 
unity for extremely large effects. Values of V, however, are generally low and 
coverage of the full range is not verified. Slightly negative values of V and R²sch in 
may occur in the case of low effect size and indicate poor impact of the genotype on 
the survival phenotype. 
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2.3.1.3 Dependence on the genetic effect size  
General dependence on the genetic effect size 
As can be seen from Figure 4, all criteria generally increase with the genetic effect 
size. The increase, however, seems also to be related to the underlying genetic effect 
model. Whereas it is clearly visible for additive and dominant genetic effect models, it 
is less clear for recessive effect models. This finding has been observed throughout 
the simulations. 
 
Dependence on variance of effect size 
The link between the criteria and effect size was further investigated through analysis 
of standard deviations of both, criteria and effect size, over the 200 simulated 
datasets within each scenario. Averaged standard deviations of the criteria in each 
scenario were generally low (Figure 4). However, comparison of results over all 
simulation scenarios showed that R²sch is most sensitive to the variance of the 
estimated effect size, which also increases with increasing censoring percentage, i.e. 
increasing uncertainty in the data. For example, for models with HR=8 in combination 
with 80% censoring, a high standard deviation of the estimated βˆ  in the 200 
datasets yielded up to 12% standard deviation for R²sch. Standard deviations of the 
criteria V (and Vw) and kd.norm also showed dependence on censoring percentage and 
the estimated effect size but hardly exceeded 4%. 
 
Summary of results: dependence on effect size 
For all criteria, the values increase for increasing effect size as postulated. The 
underlying genetic effect model, however, seems to play an important role. 
51  2. Impact of genetic variants on survival phenotypes 
 
 
Particularly the recessive effect model exhibits lower values in all criteria than the 
other genetic effect models. This is obviously due to the low genotype variance in 
recessive effect models (see section 2.3.1.2). Furthermore, R²sch is most sensitive to 
variations of the estimated effect size. Simulation settings with high variation of the 
estimated genetic effect size were observed to result in increased variation of R²sch. 
Variation of the estimated genetic effect size was found to be directly related to the 
censoring percentage in the data. Therefore, indirect influence of censoring on 
values of R²sch is possible, as described in the next section. 
 
2.3.1.4 Dependence on censoring  
Dependence on censoring mechanism 
In first instance, the two censoring mechanisms (fixed censoring and random 
censoring) were compared. The comparison revealed no major differences between 
the two scenarios in the general settings with censoring percentages below 80%. The 
criteria results from settings shown in Figure 4 for fixed censoring are displayed for 
random censoring on the same data in Figure 6. Only slight differences were 
observed: for censoring ≥80, the decrease of V in the dominant model with high 
effect size was less and R²sch was strictly robust against censoring below 80%. The 
discrepancies, however, were small. Hence, all further general examination was 
limited to simulations with fixed censoring a time C=τ, which is the more common 
situation in genetic association studies within general populations and regular follow-
ups. 
 
 
 2. Impact of genetic variants on survival phenotypes 52 
 
 
Figure 6: Survival data with random censoring were simulated for a single covariate { }2;1;0∈X  with 
sampling probabilities calculated from MAF=25%. Mean values of the investigated criteria judging the 
impact of the single genetic covariate
 
 (a) for additive and (b) dominant and (c) recessive effect models 
are plotted against hazard ratios (HR). For each value of HR, results for different censoring 
percentages (cens) are presented as different point characters (adding small scatter on the x-axis for 
differentiation). The range of standard deviations (std) averaged over the 200 simulated data sets per 
scenario is given in each panel. 
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Dependence on censoring percentage 
When investigating the dependence of kd.norm, V and R²sch on the censoring 
percentage, a distinction between the genetic effect models was necessary, again, 
due to the different range of criteria values. 
Values were high for all three criteria under the assumption of an additive or 
dominant effect model as long as censoring percentage was lower than 80%. The 
additive model generally yielded slightly higher values. Only for data with high 
censoring (≥80%), an eminent drop in V was observed in the dominant model. R²sch, 
in contrast, was even slightly higher for the dominant model than for the additive 
model in the extreme settings with HR=128 when combined with censoring ≥80%. 
For recessive effect models, all criteria had low values although a general increase 
was observed for increasing effect size (Figure 4). In contrast to the dominant model, 
V showed an eminent increase for effect size HR=128 in combination with high 
censoring percentage (≥80%).  
Especially for the additive (as well as for the dominant) effect model, a strong 
dependence of kd.norm on the censoring percentage could be seen, while the other 
criteria were more robust against censoring, at least up to 50% (Figure 4). In the 
recessive model, this dependence is not obvious. 
For R²sch, a minor dependence on censoring may be noticed for high effect sizes in 
combination with high censoring. 
 
Summary of results: dependence on censoring (c) 
A strong dependence on censoring is generally observed for kd.norm, while V and R²sch 
are more robust. With high censoring (≥80%), however, values of V and R²sch are 
also affected. In case of high censoring percentage in the data, the structure of the 
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underlying censoring mechanism influences this degree of change marginally. Both 
criteria are slightly less affected, if censoring is random and not conducted at a fixed 
point on the time scale. 
 
2.3.2 Results from simulations for a single continuous covariate 
Simulations for continuous covariates were conducted in order to observe the 
criteria’s behaviour in case of non-genetic covariates as they in a Cox model adjusted 
for environmental covariates. Chosen covariate distributions were: 
1. a standard normally distributed covariate X~N(0;1) 
2. a standard uniformly distributed covariate X~unif[0;1] 
3. a normally distributed covariate X~N(0;1/12) 
In case of a single standard normally distributed covariate, the criterion kd.norm 
exceeded the desired boundary of 1 in most situations with HR=32 and low censoring 
(Figure 7). The other criteria, however, hold the desired limit. In none of the genetic 
simulation scenarios, this exceeding of the limit was observed. 
For the standard normal covariate distribution, again, V yielded lowest values among 
the three criteria with a maximum of 71%, while R²sch reached up to 95%. Although a 
general increase with increasing effect size was observed, all criteria in this setting, 
to some extend, depended on the censoring percentage. Therefore, the precision of 
the estimation of effect sizes was also examined. While the mean values of the 
estimated hazard ratios per scenario were independent of censoring, their standard 
deviations increased with increasing censoring percentage (Table IV). In addition, a 
general dependence of standard deviations on the underlying effect size was 
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observed. Highest standard deviations were obtained for maximum censoring 
percentage in combination with maximum effect size. 
 
 
Figure 7: Criteria values for a non-genetic univariate model with one single standard normal covariate
Table IV: Standard deviations of estimated effect sizes β for a standard normally distributed covariate 
over 200 simulations dependent on censoring percentage (fixed censoring) and effect size. 
 
are plotted as average over 200 simulation scenarios against the HR from the corresponding setting 
with fixed censoring. For each value of HR, results for different censoring percentages (cens) are 
presented as different point characters (adding small scatter on the x-axis for differentiation). The 
range of standard deviations (std) averaged over the 200 simulated data sets per scenario is given in 
each panel. 
 
 cens=0% cens=10% cens=25% cens=50% cens=80% cens=90% 
β=log(1.25) 0.033 0.036 0.040 0.047 0.074 0.097 
β=log(1.5) 0.034 0.036 0.039 0.048 0.077 0.109 
β=log(2) 0.038 0.039 0.043 0.048 0.075 0.101 
β=log(4) 0.045 0.045 0.048 0.057 0.084 0.116 
β=log(8) 0.065 0.065 0.065 0.072 0.105 0.138 
β=log(32) 0.087 0.091 0.097 0.114 0.162 0.231 
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For the settings with (a) a uniformly and (b) a normally distributed covariate but both 
with equal variance (var=1/12), criteria values were similar but generally lower than 
for the setting with a single standard normally distributed covariate (Figure 8). In 
these settings too, a slight dependence of the criteria on censoring was observed. 
Like for the standard normally distributed covariate, standard deviations of effect 
estimates within each setting were found to be dependent on censoring percentage, 
while mean values were precise (data not shown). 
 
 
Figure 8: Criteria values for a non-genetic univariate model with a) a single standard uniform covariate 
X~unif[0;1] and b) a single normally distributed covariate ( )121;0~ NX  are plotted as average over 
200 simulation scenarios against the HR from the corresponding setting. For each value of HR, results 
for different censoring percentages (cens) are presented as different point characters (adding small 
scatter on the x-axis for differentiation). The range of standard deviations (std) averaged over the 200 
simulated data sets per scenario is given in each panel. 
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In conclusion, the settings with a single continuous covariate refined the insight into 
the characteristics of the investigated criteria: 
(a) Limitation to the range [0;1] is not generally guaranteed for kd.norm. In presence 
of very strong effects and high variance of the covariate, it systematically 
exceeds the desired maximum of 1. Coverage of the whole range [0;1] is 
doubted for V, as it hardly exceeds 70% even in extreme situations. Only R²sch 
seems to fully exploit the whole range while keeping the limitation. 
(b) All criteria increase with increasing effect size and increasing variance of the 
covariate. 
(c) Dependence on censoring, to some extend, is observed for all criteria. 
Especially for V and R²sch, this dependence may be due to increasing 
standard deviation of the estimated effect size with increasing censoring 
percentage. kd.norm, however, already decreases in case of small censoring 
percentage in the data, where standard deviations of the estimated effect size 
are only slightly increased. 
 
2.3.3 Results from combining a SNP with a strong continuous 
predictor 
In the case that adjustment for environmental covariates is required in genetic 
association studies, it is also important to know the criteria’s behaviour in this 
situation. Therefore, simulations with both, a SNP and continuous environmental 
covariate, were conducted. Here, a strong effect of the environmental covariate on 
the survival phenotype was assumed, as it is often the case when age or blood 
markers are included into a model. Adding the presence of a strong continuous 
predictor to the SNP simulation scenarios was established through incorporation of a 
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standard normally distributed covariate with effect size HR=exp(1)=2.72 to the 
previously investigated single SNP scenarios. 
It should be noted that all criteria, in this setting, measure the impact of the 
combination of both covariates on the phenotype. The effect of the continuous 
covariate was kept fixed in order to investigate the criteria’s behaviour in case of 
changes in the genetic effect size alone. 
Due to the high impact of the continuous covariate, all criteria values rose to a higher 
level (Figure 9). The increase due to increasing genetic effect size, however, was 
low, but still observable in the additive or dominant genetic effect model, at least in 
case of strong effects. Within recessive effect models, however, none of the criteria 
seemed to change with increasing genetic effect size. 
As in the setting with a single standard normally distributed covariate, kd.norm tended 
to exceed the desired maximum value of 1 with increasing genetic effect size in 
combination with low censoring percentages. 
Dependence on the censoring percentage was mainly visible for kd.norm under the 
assumption of an additive effect model. However, none of the criteria was unaffected 
by censoring. As in the simulations for single continuous covariates, the standard 
deviation of the estimated effect sizes, calculated over the 200 simulations within 
each setting, was dependent on the censoring percentage. Standard deviations of 
the estimated effect sizes were higher for dominant and recessive effect models than 
for additive effect models and also resulted in increased standard deviations of the 
criteria in each setting (Figure 9). 
Furthermore, average values of estimated genetic effect sizes within each setting 
were observed to not be robust against the censoring percentage in presence of a 
strong continuous predictor. Biases in averaged effect estimates of the genetic 
covariate were mainly observed for the recessive model. 
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Figure 9: Survival data were simulated for a genetic covariate { }2;1;0∈X  with sampling probabilities 
calculated from MAF=25% and a standard normally distributed covariate with fixed HR=exp(1). Mean 
values of the investigated criteria judging the impact of the genetic and the quantitative covariate 
combined (a) for additive, (b) dominant and (c) recessive effect models are plotted against hazard 
ratios (HR) of the genetic covariate. For each value of HR, results for different censoring percentages 
under the assumption of fixed censoring (cens) are presented as different point characters (adding 
small scatter on the x-axis for differentiation). The range of averaged standard deviations (std) over 
the 200 simulated data sets per scenario is given in each panel. 
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From the setting combining SNPs with a strong continuous predictor, it is concluded 
that the impact of single SNPs may be masked by the continuous covariate, 
especially when the genetic effect is small. In part, this may be explained by biased 
estimates of the genetic effect size. Biases in the genetic effect estimates are also 
related to the censoring percentage. Therefore, indirect dependence on the 
censoring percentage is observed. 
 
2.3.4 Results from real data analysis 
2.3.4.1 KORA, real SNP analysis 
From the 51 SNPs that were initially chosen for analysis, five SNPs show violation of 
HWE, 11 SNPs had MAF<10%, four SNPs show no homozygous carriers of the 
minor allele (rs17366743, rs2066860, rs707922 and ADA22) and gave rise to 
unreliable estimates for the recessive model (Table V). Only ADA22 and rs2225995 
had a genotyping success rate below 90%. No SNPs, however, were excluded from 
analysis. 
Four SNPs (rs174570, rs2225995, rs8065316, ADA22) showed association to age at 
baseline. However, none of these SNPs was significantly associated to mortality in 
any of the investigated Cox models. 
Further investigation is restricted to the eight SNPs that showed significant results on 
significance level of 5% in any of the association models. With the significance level 
corrected to 0.2% for six models and 40 independent SNPs derived from the 
correlation matrix, none of these detected significances in these SNPs, however, 
remained after correction for multiple testing. 
Only rs6808, rs3834458 and the artificially generated SNPs yielded significant 
association to a 5% significance level in SNP analysis unadjusted for age and sex  
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Table V: Description of selected SNPs investigated for this mortality study in KORA S3 (MONICA 
Augsburg Cohort Study S3, 1984-2005) including position, genotyping success rate (SR), minor allele 
frequency (MAF), p-value resulting from exact test for violation of the Hardy-Weinberg-Equilibrium 
(HWE) and disease relevant association or indication as possible candidate from genome-wide 
analysis screen (GWA). 
SNP_ID 
Chromosome / 
Position Gene SR MAF HWE Association to 
rs1234313 1 / 171432870 TNFSF4 96.6 30.7 0.8855 Atherosclerosis 
rs3850641 1 / 171442455 TNFSF4 96.2 15.1 0.6756 Atherosclerosis 
rs1234315 1 / 171445086 TNFSF4 96.7 45.4 0.5370 Atherosclerosis 
rs7566605 2 / 118552495 INSIG2 91.3 33.4 0.1284 Obesity 
rs17300539 3 / 188042154 APM1 98.2 8.6 0.7001 Plasma adiponectin 
rs17366743 3 / 188054783 APM1 98.7 2.6 0.7652 Plasma adiponectin 
rs1800791 4 / 155702759 FGB 97.6 13.5 0.4735 Fibrinogen, myocardial infarction 
rs1800788 4 / 155703364 FGB 90.9 17.9 0.5205 Fibrinogen, myocardial infarction 
rs4463047 4 / 155714983 intergenic 91.7 13.0 0.2676 Fibrinogen, myocardial infarction 
rs6825454 4 / 155720638 intergenic 98.1 25.5 0.2154 Fibrinogen, myocardial infarction 
rs2070022 4 / 155724398 FGA 99.0 16.3 0.2025 Fibrinogen, myocardial infarction 
rs2070016 4 / 155729764 FGA 91.8 14.9 0.2651 Fibrinogen, myocardial infarction 
rs2066861 4 / 155746886 FGA 98.9 24.4 1 Fibrinogen, myocardial infarction 
rs2066860 4 / 155748924 FGG 93.8 3.8 0.1936 Fibrinogen, myocardial infarction 
rs1800792 4 / 155753858 FGG 93.1 46.6 0.0450 Fibrinogen, myocardial infarction 
rs10012555 4 / 155870881 intergenic 94.3 11.4 0.5903 Fibrinogen, myocardial infarction 
rs10520818 5 / 15642917 FBXL7 98.8 12.2 0.8873 GWA 
rs707922 6 / 31733486 APOM 99.5 6.6 0.5398 HDL cholesterol 
rs1800796 7 / 22732771 IL6 99.2 5.7 0.4005 Diabetes 
rs1800795 7 / 22733170 IL6 99.5 43.7 0.7827 Diabetes 
rs1105218 8 / 12700580 intergenic 97.4 15.4 0.7251 GWA 
rs1248696 10 / 79286611 DGL5 99.3 9.6 0.7934 inflammatory bowel disease 
rs1528133 11 / 8106329 RIC3 99.3 6.3 0.0195 nicotinic acetylcholine receptors 
rs2071212 11 / 61287413 C11orf9 94.7 32.3 0.9437 Fatty acids, atopy 
rs174528 11 / 61300075 C11orf9 97.3 33.6 0.4519 Fatty acids, atopy 
rs174538 11 / 61316656 C11orf9 97.3 26.6 0.8760 Fatty acids, atopy 
rs174544 11 / 61324329 FADS1 94.0 26.6 0.7207 Fatty acids, atopy 
rs174553 11 / 61331734 FADS1 94.6 30.8 0.0885 Fatty acids, atopy 
rs174556 11 / 61337211 FADS1 94.2 26.7 0.9369 Fatty acids, atopy 
rs174561 11 / 61339284 FADS1 97.1 25.5 0.0220 Fatty acids, atopy 
rs3834458 11 / 61351497 FADS2 93.4 30.1 0.8244 Fatty acids, atopy 
rs99780 11 / 61353209 FADS2 97.6 30.2 0.1699 Fatty acids, atopy 
rs174570 11 / 61353788 FADS2 94.7 10.5 0.0316 Fatty acids, atopy 
rs2072114 11 / 61361791 FADS2 93.5 10.2 0.3064 Fatty acids, atopy 
rs174583 11 / 61366326 FADS2 93.1 31.6 0.6654 Fatty acids, atopy 
rs174602 11 / 61380990 FADS2 94.7 17.9 0.5629 Fatty acids, atopy 
rs482548 11 / 61389758 FADS2 95.4 9.4 0.7862 Fatty acids, atopy 
rs174454 11 / 61407323 FADS3 93.1 23.9 0.5482 Fatty acids, atopy 
rs528285 11 / 61417280 FADS3 97.3 33.0 0.1048 Fatty acids, atopy 
rs10507197 12 / 104585833 intergenic 95.0 40.8 0.5022 GWA 
rs1543480 14 / 45533589 intergenic 95.2 49.8 0.7344 GWA 
rs2225995 14 / 48124872 intergenic 84.5 8.1 0.3789 GWA 
rs2400464 14 / 98433397 intergenic 97.7 37.3 0.1823 GWA 
rs293004 15 / 58058615 RAB3C 99.0 42.0 0.6418 GWA 
rs1588085 15 / 96117717 intergenic 97.6 3.3.0 0.1484 GWA 
rs6808 17 / 59754307 PECAM1 98.8 48.1 0.6713 CAD 
rs8065316 17 / 59816347 PECAM1 90.6 46.6 0.0057 CAD 
rs1390428 18 / 32457205 FHOD3 99.1 12.6 0.1310 GWA 
ADA22 20 / 42713641 ADA 84.6 5.7 0.3641 duration and intensity of deep sleep 
rs2038526 20 / 48619056 PTPN1 99.3 36.4 1 Diabetes 
rs5751876 22 / 23167301 ADORA2A 94.3 39.6 0.6504 duration and intensity of deep sleep 
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(Table VIa). After adjustment for sex and age, five more SNPs showed significant 
association in any of the proposed genetic effect models (Table VIb). A last SNP 
(rs1543480) chosen for closer investigation was found to be associated with age at 
death under the assumption of a recessive genetic effect model (Table VIc). None of 
these altogether eleven SNPs violated the HWE assumption. The significance 
obtained for rs3834458 under a recessive effect model disappeared after adjusting 
for sex and age. 
Lowest p-values were observed for two SNPs located within the fibrinogen gene 
(rs2070016 and rs10012555) in the age and sex adjusted model under the 
assumption of a recessive effect. An effect of these SNPs could not be seen for any 
of the other models. 
Investigation of the criteria kd.norm, V and R²sch in the three genetic effect models 
showed that none of the real SNPs has a high contribution to the fit of the model 
(Table VIa). Like in the simulation studies, values of Vw were very close to V with a 
tendency to be slightly smaller. Therefore, results for Vw are not discussed in detail. 
The criteria kd.norm and R²sch reach up to 4%, whereas V yields values below 0.1%. 
These rather low values, however, are in the generally reported range of R² from 
SNP association analysis with quantitative phenotypes. For the adjusted models as 
well as for the models with age at death as outcome, no obvious deviation from the 
criteria values for the non-genetic models is obvious for any of the SNPs (Table VIb 
and c). It should be noted that criteria values for non-genetic models varied slightly, if 
observations with missing genotypes were excluded. Therefore, values in the genetic 
models may be slightly lower than in the non-genetic model without exclusion of 
these observations. 
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Table VI: R
eal data: For the three different genetic effect m
odels (additive, dom
inant, recessive), estim
ated hazard ratios (H
R
) and corresponding p-values (p) 
for the seven S
N
Ps from
 the KO
R
A data that show
ed p< 0.05 in any of these m
odels as w
ell as the three artificial lethal S
N
Ps. Estim
ates w
ere derived by C
ox 
regression (a) w
ithout and (b) w
ith adjusting for age and sex
† for analysis of tim
e since baseline survey S3 and (c) age at death adjusted for sex. Also stated are 
criteria values K
d.norm , V
, V
w  and R
²sch . 
 (a) 
 
additive effect m
odel 
dom
inant effect m
odel 
recessive effect m
odel 
 
SN
P
 
H
R
 
p 
K
d.norm  
V
 
V
w  
R
²sch  
H
R
 
p 
K
d.norm  
V
 
V
w  
R
²sch  
H
R
 
p 
K
d.norm  
V
 
V
w  
R
²sch 
 R
eal S
N
P
s : 
rs17300539 0.806 0.150 0.0236 
4*10
-4 
3*10
-4 
0.0067 
0.774 0.110 
0.0267 
5*10
-4 
4*10
-4 
0.0089 
1.136 
0.830 
9*10-4 
0 
0 
2*10
-4 
rs17366743* 0.566 0.074 0.0186 
4*10
-4 
3*10
-4 
0.0195 
0.567 0.077 
0.0184 
4*10
-4 
3*10
-4 
0.0185 
--- 
--- 
--- 
--- 
--- 
--- 
rs2070016 
1.124 0.280 0.0210 
1*10
-4 
1*10
-4 
0.0051 
1.079 0.550 
0.0124 
0 
0 
0.0020 
1.697 
0.073 
0.0124 
6*10
-4 
5*10
-4 
0.0096 
rs10012555 1.057 0.640 0.0081 
1*10
-4 
1*10
-4 
2*10
-4 
1 
1 
0 
0 
0 
0 
1.895 
0.074 
0.0088 
7*10
-4 
5*10
-4 
0.0050 
rs10520818 1.125 0.300 0.0184 
2*10
-4 
1*10
-4 
0.0038 
1.231 0.096 
0.0309 
4*10
-4 
3*10
-4 
0.0079 
0.198 
0.110 
0.011 
5*10
-4 
4*10
-4 
0.0405 
rs3834458 
0.915 0.310 0.0211 
1*10
-4 
1*10
-4 
0.0039 
0.987 0.900 
0.0027 
0 
0 
0 
0.612 
0.038 
0.0283 
7*10
-4 
5*10
-4 
0.0212 
rs1543480 
0.897 0.170 0.0223 
3*10
-4 
3*10
-4 
0.0083 
0.958 0.730 
0.0066 
0 
0 
0.001 
0.767 
0.056 
0.0375 
8*10
-4 
6*10
-4 
0.0133 
rs6808 
1.164 0.050 0.0309 
6*10
-4 
5*10
-4 
0.0133 
1.315 0.038 
0.0416 
6*10
-4 
5*10
-4 
0.0162 
1.148 
0.270 
0.0205 
2*10
-4 
2*10
-4 
0.0038 
 A
rtificial lethal SN
Ps for three different degrees lethality:  
M
oderate 
1.577 <10
-10 0.3526 
0.1022 
0.0803 
0.3724 
1.167 <10
-10 
0.2276 
0.0132 
0.0106 
0.2623 
2.832 
<10
-10 
0.2853 
0.1579 
0.1239 
0.3953 
S
trong 
2.472 <10
-10 0.4760 
0.2834 
0.2242 
0.6002 
1.956 <10
-10 
0.3512 
0.0293 
0.0235 
0.5456 
3.802 
<10
-10 
0.4144 
0.3542 
0.2797 
0.6189 
E
xtrem
e 
56.120 <10
-10 0.6133 
0.5484 
0.4315 
0.9345 
78.218 <10
-10 
0.5385 
0.0395 
0.0354 
0.9405 
155.400 
<10
-10 
0.5545 
0.6750 
0.5201 
0.8601 
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(b)  † 
 
additive effect m
odel 
dom
inant effect m
odel 
recessive effect m
odel 
 
SN
P
 
H
R
 
p 
K
d.norm  
V
 
V
w  
R
²sch  
H
R
 
p 
K
d.norm  
V
 
V
w  
R
²sch  
H
R
 
p 
K
d.norm  
V
 
V
w  
R
²sch 
 R
eal S
N
P
s : 
rs17300539 
0.758 
0.069 0.4491 
0.1044 
0.0808 
0.7635 
0.721 0.044 0.4493 
0.1046 
0.0810 
0.7647 
1.227 0.720 0.4481 
0.1028 
0.0795 
0.7651 
rs17366743* 
0.498 
0.028 0.4485 
0.1036 
0.0802 
0.7563 
0.498 0.030 0.4484 
0.1035 
0.0801 
0.7562 
--- 
--- 
--- 
--- 
--- 
--- 
rs2070016 
1.168 
0.160 0.4399 
0.0970 
0.0750 
0.7550 
1.088 0.500 0.4393 
0.0964 
0.0744 
0.7547 
2.332 0.004 0.4417 
0.0986 
0.0764 
0.7567 
rs10012555 
1.110 
0.390 0.4422 
0.1048 
0.0810 
0.7569 
1.043 0.750 0.4419 
0.1042 
0.0805 
0.7581 
2.327 0.018 0.4430 
0.1065 
0.0826 
0.7570 
rs10520818 
1.166 
0.180 0.4442 
0.1008 
0.0778 
0.7648 
1.279 0.048 0.4445 
0.1017 
0.0784 
0.7652 
0.209 0.120 0.4460 
0.1015 
0.0784 
0.7611 
rs3834458 
0.928 
0.390 0.4367 
0.1003 
0.0774 
0.7536 
0.999 0.990 0.4365 
0.0998 
0.0770 
0.7550 
0.638 0.057 0.4381 
0.1017 
0.0785 
0.7534 
rs1543480 
0.957 
0.570 0.4513 
0.1057 
0.0816 
0.7663 
1.100 0.46 
0.4515 
0.1062 
0.0821 
0.7647 
0.785 0.082 0.4525 
0.1065 
0.0823 
0.7692 
rs6808 
1.165 
0.049 0.4445 
0.1018 
0.0788 
0.7645 
1.306 0.043 0.4447 
0.1023 
0.0792 
0.7617 
1.158 0.240 0.4437 
0.1007 
0.0779 
0.7646 
 A
rtificial lethal SN
Ps for three different degrees lethality:  
M
oderately 
1.403 
<10
-10 0.5073 
0.2356 
0.1892 
0.7716 
1.033 <10
-10 0.4610 
0.1254 
0.0975 
0.9204 
2.555 <10
-10 0.4878 
0.2907 
0.2369 
0.7744 
H
ighly 
2.191 
<10
-10 0.5835 
0.4046 
0.3292 
0.7937 
1.796 <10
-10 0.4966 
0.1585 
0.1229 
0.9353 
3.429 <10
-10 0.5018 
0.4595 
0.3757 
0.8130 
E
xtrem
ely 
39.770 
<10
-10 0.6550 
0.6006 
0.4852 
0.9592 
75.790 <10
-10 0.6281 
0.2057 
0.1608 
0.9453   103.340 <10
-10 0.5747 
0.6074 
0.4858 
0.9188 
 * no hom
ozygous carriers of the m
inor allele observed in the group of cases 
† The m
odel for age and sex alone yields hazard ratios of H
R
=0.485 for age and H
R
=1.115 for sex=w
om
an. B
oth p-values are below
 10
-9 and the follow
ing values are 
obtained for the criteria: K
d.norm =0.4458, V
 =0.1027, V
w =0.0794 and R
²sch =0.7658. 
  (c)  † 
 
additive effect m
odel 
dom
inant effect m
odel 
recessive effect m
odel 
 
SN
P
 
H
R
 
p 
K
d.norm  
V
 
V
w  
R
²sch  
H
R
 
p 
K
d.norm  
V
 
V
w  
R
²sch  
H
R
 
p 
K
d.norm  
V
 
V
w  
R
²sch 
 R
eal S
N
P
s : 
rs17300539 
0.805 
0.150 0.1503 
0.0080 
0.0062 
0.1310 
0.774 0.110 0.1499 
0.0080 
0.0063 
0.1330 
1.059 0.920 0.1502 
0.0076 
0.0059 
0.1236 
rs17366743 
0.566 
0.074 0.1511 
0.0077 
0.0060 
0.1304 
0.567 0.078 0.1509 
0.0077 
0.0060 
0.1298 
--- 
--- 
--- 
--- 
--- 
--- 
rs2070016 
1.120 
0.300 0.1323 
0.0061 
0.0049 
0.1000 
1.069 0.600 0.1324 
0.0060 
0.0047 
0.0972 
1.759 0.055 0.1343 
0.0066 
0.0053 
0.1006 
rs10012555 
1.075 
0.550 0.1496 
0.0081 
0.0063 
0.1210 
1.018 0.890 0.1495 
0.0080 
0.0062 
0.1213 
1.968 0.059 0.1510 
0.0088 
0.0069 
0.1229 
rs10520818 
1.146 
0.230 0.1464 
0.0075 
0.0058 
0.1210 
1.263 0.061 0.1465 
0.0079 
0.0061 
0.1247 
0.192 0.100 0.1519 
0.0079 
0.0061 
0.1439 
rs3834458 
0.904 
0.250 0.1486 
0.0080 
0.0062 
0.1242 
0.975 0.820 0.1486 
0.0078 
0.0060 
0.1198 
0.598 0.030 0.1545 
0.0086 
0.0067 
0.1390 
rs1543480 
0.888 
0.130 0.1412 
0.0074 
0.0058 
0.1171 
0.940 0.630 0.1413 
0.0070 
0.0055 
0.1102 
0.761 0.049 0.1409 
0.0078 
0.0061 
0.1243 
rs6808 
1.164 
0.049 0.1489 
0.0082 
0.0064 
0.1370 
1.327 0.032 0.1492 
0.0083 
0.0065 
0.1348 
1.139 0.300 0.1489 
0.0077 
0.0060 
0.1290 
 * no hom
ozygous carriers of the m
inor allele observed in the group of cases 
† The m
odel for sex alone yields H
R
=0.458 for sex=w
om
an w
ith p-value below
 10
-10 and the follow
ing values are obtained for the criteria: K
d.norm =0.1523, V
 =0.0079, 
V
w =0.0062 and R
²sch =0.1272. 
 (b)  † 
 
additive effect m
odel 
dom
inant effect m
odel 
recessive effect m
odel 
 
SN
P
 
H
R
 
p 
K
d.norm  
V
 
V
w  
R
²sch  
H
R
 
p 
K
d.norm  
V
 
V
w  
R
²sch  
H
R
 
p 
K
d.norm  
V
 
V
w  
R
²sch 
 R
eal S
N
P
s : 
rs17300539 
0.758 
0.069 0.4491 
0.1044 
0.0808 
0.7635 
0.721 0.044 0.4493 
0.1046 
0.0810 
0.7647 
1.227 0.720 0.4481 
0.1028 
0.0795 
0.7651 
rs17366743* 
0.498 
0.028 0.4485 
0.1036 
0.0802 
0.7563 
0.498 0.030 0.4484 
0.1035 
0.0801 
0.7562 
--- 
--- 
--- 
--- 
--- 
--- 
rs2070016 
1.168 
0.160 0.4399 
0.0970 
0.0750 
0.7550 
1.088 0.500 0.4393 
0.0964 
0.0744 
0.7547 
2.332 0.004 0.4417 
0.0986 
0.0764 
0.7567 
rs10012555 
1.110 
0.390 0.4422 
0.1048 
0.0810 
0.7569 
1.043 0.750 0.4419 
0.1042 
0.0805 
0.7581 
2.327 0.018 0.4430 
0.1065 
0.0826 
0.7570 
rs10520818 
1.166 
0.180 0.4442 
0.1008 
0.0778 
0.7648 
1.279 0.048 0.4445 
0.1017 
0.0784 
0.7652 
0.209 0.120 0.4460 
0.1015 
0.0784 
0.7611 
rs3834458 
0.928 
0.390 0.4367 
0.1003 
0.0774 
0.7536 
0.999 0.990 0.4365 
0.0998 
0.0770 
0.7550 
0.638 0.057 0.4381 
0.1017 
0.0785 
0.7534 
rs1543480 
0.957 
0.570 0.4513 
0.1057 
0.0816 
0.7663 
1.100 0.46 
0.4515 
0.1062 
0.0821 
0.7647 
0.785 0.082 0.4525 
0.1065 
0.0823 
0.7692 
rs6808 
1.165 
0.049 0.4445 
0.1018 
0.0788 
0.7645 
1.306 0.043 0.4447 
0.1023 
0.0792 
0.7617 
1.158 0.240 0.4437 
0.1007 
0.0779 
0.7646 
 A
rtificial lethal SN
Ps for three different degrees lethality:  
M
oderate 
1.403 
<10
-10 0.5073 
0.2356 
0.1892 
0.7716 
1.033 <10
-10 0.4610 
0.1254 
0.0975 
0.9204 
2.555 <10
-10 0.4878 
0.2907 
0.2369 
0.7744 
S
trong 
2.191 
<10
-10 0.5835 
0.4046 
0.3292 
0.7937 
1.796 <10
-10 0.4966 
0.1585 
0.1229 
0.9353 
3.429 <10
-10 0.5018 
0.4595 
0.3757 
0.8130 
E
xtrem
e 
39.770 
<10
-10 0.6550 
0.6006 
0.4852 
0.9592 
75.790 <10
-10 0.6281 
0.2057 
0.1608 
0.9453   103.340 <10
-10 0.5747 
0.6074 
0.4858 
0.9188 
 * no hom
ozygous carriers of the m
inor allele observed in the group of cases 
† The m
odel for age and sex alone yields hazard ratios of H
R
=0.485 for age and H
R
=1.115 for sex=w
om
an. B
oth p-values are below
 10
-9 and the follow
ing values are 
obtained for the criteria: K
d.norm =0.4458, V
 =0.1027, V
w =0.0794 and R
²sch =0.7658. 
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  (c)  † 
 
additive effect m
odel 
dom
inant effect m
odel 
recessive effect m
odel 
 
SN
P
 
H
R
 
p 
K
d.norm  
V
 
V
w  
R
²sch  
H
R
 
p 
K
d.norm  
V
 
V
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2.3.4.2 Analysis of artificial SNPs in KORA 
For the artificially generated SNPs, all criteria values were substantially higher with 
an increase with increasing lethality, as postulated. Highest values throughout all the 
models were obtained for R²sch for the “extreme SNP” (with R²sch>0.86), which was 
generated to yield almost perfect association to mortality and therefore values close 
to 1 in all criteria. All criteria’s connection to the estimated hazard ratio and the p-
value was apparent as they increased either with the distance of the estimated 
hazard ratio from 1 (null effect) or with decrease in the p-value. 
For the initially generated artificial SNP, the true effect model was known. For 
generation of SNPs with different degrees of association to mortality, different 
percentages of the genotypes from this original SNP were randomly assigned. 
Therefore, it cannot be guaranteed that with increasing random assignment of 
genotypes, the original genetic effect model is kept for these SNPs. The effect of 
misspecification of the assumed effect model on the criteria could be seen best for 
the “extreme SNP”, which is closest to the original SNP. The two derived SNPs with 
lower association to mortality, however, were not excluded from this analysis. 
V obviously suffered from a substantial drop in value under the false assumption of a 
dominant effect for all artificially generated SNPs, while the other criteria were less 
affected. In addition, V would clearly have favoured the recessive over the additive 
model, while only kd.norm yields highest values for the additive model. For R²sch, a 
decision between the additive effect model and one of the dichotomous effect models 
was difficult in the unadjusted model. In the adjusted model, the correct model would 
have been favoured only for the “extremely lethal” SNP. For the two other SNPs, the 
dominant effect model yielded highest values. The Kaplan Meier survival curves 
obtained for the “extreme SNP” is displayed in Figure 10. The major discrepancy 
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between the curves was found for homozygous carriers of the minor allele and 
censored times were highly clustered at the end of the study period. 
 
 
Figure 10: Kaplan-Meier curves obtained for genotypes of the “extreme SNPl” artificially generated 
SNP (homozygous carriers of the major allele, heterozygotes, homozygous carriers of the minor 
allele). 
 
After adjustment for sex and age, the criteria’s values increased substantially for all 
artificial SNPs (Table VIb). However, differences between criteria values of the 
models were low, which indicates that the major increase of the predictive capability 
discovered by all criteria was due to adjustment alone. Compared to real SNPs, the 
gain in value obtained for the artificially generated SNPs after adjustment for sex and 
age was smaller for all criteria. V and Vw, again, were substantially smaller under the 
assumption of a dominant effect compared to the other genetic effect models. 
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3 Discussion 
3.1 Overview 
It is of increasing interest to quantify the impact of genetics on health related 
parameters or disease development. A generally comprehensible measure apart, 
from effect size and p-value, is the percentage of the impact on the phenotype which 
can be explained through genetic variation alone. In case of continuously measured 
health parameters (e.g. blood parameters), it is easy to judge the percentage of 
variation in the health parameter that can be explained by variation in genetic 
variants. The appropriate measure R² is included as standard output in association 
analysis software. For case-control studies a derivation of R² for logistic regression 
models is also available. 
Meanwhile, more and more population-based studies provide follow-up data and 
allow for analysing mortality or time of occurrence of disease. These analyses, 
however, require application of methods from the statistical field of survival analysis. 
Here, the phenotype is a composition of two variables: the indicator of the health 
state at the end of the observation time and the length of the observation time. This 
special situation, without a clear definition of residuals, makes it difficult to define a 
measure comparable to R². If, for example, the impact of a genetic variant on early 
occurrence of type 2 diabetes is to be judged, the investigator is usually confronted 
with a variety of available criteria. Without deeper knowledge about the structure of 
the available criteria and their interpretation, the proper choice becomes a 
challenging task. 
The aim of this thesis was to identify a criterion which is eligible for analysis of 
survival data while being close to classical R² and its interpretation as percentage of 
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explained variation in the phenotype. Furthermore, the identified criterion was 
required to be applicable to genetic data, which is often categorical with low number 
of categories. Appropriate requirements were defined and eligible criteria were 
selected after a thorough literature review focusing on established as well as less 
known criteria. Simulation studies with a broad variety of settings for genetic data (in 
form of SNPs) and real data analysis were then conducted and gave insight into 
strengths and limitations of the selected criteria. 
As expected, no perfect solution could be found. Limitation behaviour (0%-100%) 
and dependence on censoring (percentage of observations that are still under 
observation at the end of the study period) turned out to be major or minor nuisances 
for all criteria. Some of which, however, can be explained through indirect 
dependence on the estimation under the standard Cox proportional hazards 
regression model. Therefore, as a side effect of the study, further insight into the 
special characteristics of the Cox proportional hazards model was gained, which is of 
importance for genetic as well as non-genetic association studies. The detailed 
discussion of results is given in the following chapters. After this and accounting for 
additional properties leads to the conclusion that a clear recommendation of a 
criterion comparable to classical R² can be established for application for genetic 
association with survival phenotypes. 
 
3.2 Main results 
Judging the impact of covariates in survival analysis through measures of explained 
variation, like the R² measure in linear regression, touches a general problem of 
statistics with a variety of answers. It was the aim of this investigation to identify the 
criterion that suits best to quantify the impact of genetic variants (i.e. binary or 
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trichotomous covariates for SNP genotypes) on survival phenotypes. A suitable 
criterion was expected to fulfil the following three requirements: 
(a) reasonable criteria values in the range [0;1] in order to allow for interpretation 
as percentage of prediction quality 
(b) increasing values with increasing effect size 
(c) independence of the percentage of censored observations in the data 
 
Literature review revealed three different criteria that were considered potentially 
eligible for this purpose. The first criterion, kd.norm, is based on absolute differences in 
deviance residuals between null model and covariate model. The next criterion, V, 
aims to measure the difference in variation of the individual survival curves between 
the two models. For criterion V, a variant Vw exists, which is characterised by a 
different scheme of weighting and integrating but yields values generally close to V. 
The last criterion selected for investigation, R²sch, is close to traditional R² in linear 
regression, and is defined based on the weighted sums of squared Schoenfeld 
residuals. 
Through extensive simulation studies, it was observed that none of the investigated 
criteria completely fulfils the predefined requirements. 
 
The main findings with respect to the three predefined requirements are discussed in 
the following: 
a) The requirement of limitation to the desired range [0;1] – which is important for 
interpretation as percentage – was fulfilled by all criteria for mean values across 
the 200 simulation runs per scenario, at least in all single SNP simulations. Note 
that in the rare instances with low effect size, where V (and Vw) and R²sch yielded 
slightly negative values (> -1%), the fit of the null model is slightly better than the 
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fit of the covariate model and an improvement of the model cannot be seen. 
These values, therefore, may be interpreted as zeros and are not considered to 
be major problems. Simulations with continuous covariates, however, revealed 
that the required limitation is not generally guaranteed for kd.norm. Furthermore, V 
seems not to cover the full range [0;1] and yields generally low values. The range 
of criteria values could also be linked to the genotype variance. High MAF, and 
therefore high genotype variance, resulted in higher criteria values, which is in 
line with the general properties of R²-like criteria. Generally, it could be seen that 
the impact of SNPs with recessive effects on survival time in the overall 
population is mostly low and only visible in the presence of high MAF (or 
genotypic variance) or strong effects. This is most likely due to the lower power 
and generally less explained variation in the phenotype for recessive effect 
models. This general problem, on the other hand, is not only observed for survival 
data. 
b) All investigated criteria generally increased with increasing effect size. The 
estimated effect sizes, however, were potentially biased in presence of strong 
continuous predictors. Furthermore, the variance of the estimated effect sizes 
was found to be dependent on the censoring percentage in the data. Increased 
imprecision of the effect estimate in case of high censoring, therefore, resulted in 
indirect dependence on censoring of the criteria. 
c) The two chosen censoring mechanisms representing the two most common study 
designs in cohort studies hardly affected the criteria values. Minor discrepancies 
for high censoring percentages can be explained through slightly more robust 
estimation of effect sizes under the assumption of random censoring. kd.norm 
generally strongly depended on the percentage of censored observations in the 
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data. For the other two criteria, observed dependencies can mainly be explained 
through increased variation of the estimated effect size as mentioned above. 
 
3.3 Criteria selection 
After a thorough literature search, the investigation was restricted to the criteria 
kd.norm, V and R²sch, although a broad variety is available, due to several reasons: 
• Likelihood-based criteria like AIC were excluded due to their lack of 
interpretation although they are still recommended for additional source of 
information in model selection. 
• Harrell’s C-index is calculated from the receiver operator characteristic (ROC) 
[Harrell, Jr. et al., 1982], [Harrell, Jr., 2001] based on risk ranks and is 
therefore independent of the underlying effect size [Cook, 2007], which 
violates one of the predefined general requirements. 
• The Brier score was originally developed for logistic regression and also found 
adaptation to survival data [Graf et al., 1999], [Schumacher et al., 2003], 
[Gerds and Schumacher, 2006]. As a time-dependent measure of mean 
squared error based on the considerations of [Korn and Simon, 1990], 
integration of the Brier score over time was proposed as a criterion measuring 
the predictive capability of the model. A direct correspondence to the 
investigated criterion V has been shown and comparable performance was 
concluded [Gerds and Schumacher, 2006]. The criterion Vw was described as 
interesting alternative to V [Schemper and Henderson, 2000], and thus it was 
decided to include V as well as Vw, but with a focus on V. 
• Two criteria measuring the separation of survival curves were proposed 
[Sauerbrei et al., 1997], [Royston and Sauerbrei, 2004]. The first of which is 
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based on mean absolute differences between the estimated effect sizes βˆ  
and their estimated mean. Therefore, this definition is close to the investigated 
criterion kd.norm. The second proposed criterion is based on the variation of the 
prognostic index. Hence, it is more appropriate for association analysis with 
continuous covariates and not for categorical data such as tri- or dichotomous 
SNP data. 
Therefore, the criteria kd.norm, V and R²sch were identified as the most promising and 
representative measures and were thoroughly investigated for application in genetic 
association studies with survival phenotypes. 
 
3.4 Criteria characterisation 
3.4.1 Characteristics of kd.norm 
kd.norm is the only criterion that is calculated per subject, independent of its event 
status indicator. Apart from the advantage of easy calculation of kd.norm, this criterion 
emerged as the only criterion that clearly identifies the correct genetic effect model in 
the presented real data setting with the artificially generated SNPs for crude as well 
as for age- and sex-adjusted analysis, which could be of advantage in application for 
model selection. But more detailed evaluation is needed to clarify whether this 
observation may be generalised. 
Drawbacks of kd.norm are: 1) its strong dependence on censoring and 2) the violation 
of the limitation to the range [0;1] in presence of strong continuous predictors. These 
drawbacks can be explained as follows: 
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1) In contrast to the other criteria considered here, kd.norm is not corrected for 
censoring, which explains the observed strong dependence on the censoring 
percentage in the analysed data. 
2) For some settings with a normally distributed covariate, kd.norm exceeded the 
desired maximum value of 1. Generally, this is considered to be an indication 
for some misspecification [Kvalseth, 1985]. In the present study, it is likely to 
result from the strongly skewed distribution of martingale residuals in the 
range [ ]1,∞− . Deviance residuals are normalised transformations of 
martingale residuals. In case of high cumulative hazards, as they may occur 
for highly varying covariate values, normalisation fails and the deviance 
residuals also tend to extreme values in the covariate model. Therefore, their 
expected value can deviate from 0, as exemplified in Figure 11. In case of 
deviation of the deviance residuals’ mean value from 0, limitation of kd.norm to 
the range of [0;1] is not guaranteed – especially in association analysis with 
adjustment for environmental covariates. In real data single SNP analysis 
without adjustment for other covariates, though, the situation with kd.norm 
exceeding 1 is very unlikely to occur due to the limited variation of the di- or 
trichotomous SNP covariate under the assumption of HWE and the limited 
range of realistic genetic effect sizes. 
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Figure 11: Martingale and deviance residuals are displayed for a model with uncensored 
exponentially distributed survival times associated with a standard normally distributed covariate with 
HR=32. For deviance residuals a horizontal line indicates the residual mean value which deviates from 
zero. 
 
3.4.2 Characteristics of V 
The criterion V, in contrast to kd.norm, was limited to the range [0;1] and was robust 
against moderate censoring in the data. The variant Vw yielded similar, but slightly 
lower values than V throughout the simulations. Therefore, it is not discussed in 
detail. Major drawbacks of V are: 1) its generally low values and 2) its sensitivity to 
high censoring in the data. These drawbacks and related problems are discussed as 
follows: 
1) In all simulation settings as well as for the real data examples with the 
artificially generated lethal SNPs, these values hardly exceeded 60%. This 
may indicate a generally different boundedness with the maximum attainable 
value <1. Especially recessive effect models with low power can hardly be 
differentiated. 
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2) V emerged to be sensitive to high censoring percentages, especially if the 
censoring accumulates at the end, which is often the case for real data with a 
predefined follow-up period. In these cases, values are very low, which may 
be due to the extremely low variation of the survival curves. The proper choice 
of the genetic effect model, here, also plays an important role - as could be 
seen for the presented mortality data analysis with the artificially generated 
SNPs. V suffered from a substantial drop under the false assumption of a 
dominant effect and for crude as well as for adjusted analysis, the false 
recessive effect model yielded clearly higher values than the true additive 
model. If specification of the genetic effect model would have been based on 
V, the wrong model would therefore be chosen. As V is calculated based on 
survival curves, this circumstance, however, is likely to be due to the fact that 
the discrepancy of the survival curves is lowest under the assumption of a 
dominant effect model and highest under the assumption of a recessive effect 
model (see Figure 10). 
 
3.4.3 Characteristics of R²sch 
R²sch, apart from some rare cases with slightly negative values, generally held the 
limitation to the range [0;1], which is, obviously in contrast to V, fully exploited. The 
investigations revealed that, among all investigated criteria, only R²sch was able to 
approach (and not exceed) the maximum value 1 in realistic situations, where the 
main influence on disease emerges from a strong quantitative prognostic factor, 
while the genetic component only gives small additional rise in risk. 
Among all criteria, R²sch showed strongest dependence on the effect size and its 
estimation. As estimation of βˆ  may be affected by the censoring percentage in the 
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data, R²sch also shows indirect dependence on censoring (see section 3.1). Mean 
values of the criterion, however, are not affected in the presented simulation studies 
and no general strong dependence on censoring, as for kd.norm, is obvious. 
Minor drawbacks of R²sch: 
1) As R²sch is dependent on the variance of the genetic covariate, its applicability 
to differentiate between different genetic effect models may be questionable. 
2) Its interpretation as a measure of variation in the covariates given failure time 
may be confusing. But this apparently reverse way of conditioning is justified 
after closer inspection of the Cox model (see definition of the score function) 
and therefore straightforward [Xu, 1996], [Xu and O'Quigley, 1999]. 
 
3.5 Outlook 
3.5.1 Strengths and limitations 
The major strength of this study was the high variety of simulation settings covering 
realistic as well as extreme settings with respect to: 
• genetic effect sizes 
• genotype distributions (varying MAF with and without HWE) 
• genetic effect models 
• censoring percentage in the data as well as censoring mechanism 
• continuous covariate distributions (as single prognostic factor or as additional 
adjustment covariate) 
Variation of all these parameters allowed extensive comparison of the investigated 
criteria and evaluation of their sensitivity to a variety of components in combination. 
The availability of mortality data from KORA S3/F3 allowed for judgement of the 
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criteria’s performance in realistic situations, where only small impact of genetic 
variants on survival phenotypes is expected to occur. The additionally simulated 
artificial SNPs gave insight on how the criteria would perform in case a SNP of the 
defined degree of association to mortality existed and how they react if adjustment 
for environmental factors with true effects on the survival phenotype is included. 
Although the simulation study already involved lots of tuning parameters, there could 
be further items of interest, e.g.: 
• situations with more than one single SNP 
• varying effect sizes for the environmental covariate in the bivariate simulations 
• other genetic variants like haplotypes that are possibly not coded as 
dichotomous or trichotomous covariates 
• inclusion of a set of environmental covariates, confounders or gene-
environment interactions  
The KORA mortality data example was added in order to investigate the criteria’s 
performance in real data situations. However, no strong associations were detected. 
This gap was filled through simulation of artificial SNPs based on the mortality data. 
On the other hand, it could also be interesting to investigate more complex models, 
e.g. include more environmental factors for adjustment, to analyse cause-specific 
mortality or other survival phenotypes like incident type 2 diabetes or myocardial 
infarction. 
 
3.5.2 Possible applications and extensions of R²sch 
Major advantages of R²sch are its ease of computation and its high flexibility. Lots of 
additional properties and extensions have already been described in the literature. 
Comparable information is not yet available for the other criteria investigated in this 
study. Some of the additional properties and possible extensions should be 
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mentioned here, as they can easily be realised for R²sch due to its direct connection to 
the score function of the partial likelihood: 
Similar to R² for linear regression, R²sch allows for decomposition into sums of 
squares and interpretation as proportion of variation explained by the model at least 
asymptotically. 
In addition, it is possible to calculate confidence intervals by recalculating R²sch for 
estimated confidence limits of βˆ , which is realised through simple replacement of 
the point estimate of βˆ  by it’s a) upper and b) lower confidence limit. For the other 
criteria the calculation would be more complex as the effect estimate is only 
incorporated indirectly in their definition. 
Furthermore, R²sch can easily be extended to situations where the assumption of 
proportional hazards is violated. In case of non-proportional hazards, a possible 
solution is to let at least one effect estimate vary over time as a time-varying 
coefficient ( )tβ . Another solution could be stratified analysis. These and other 
extended settings and possible tests are discussed and presented in [Therneau 
and Grambsch, 2000]. For time-varying models, it is also possible to define 
Schoenfeld residuals and R²sch due to the direct connection to the score function. 
This has been exemplified by [Xu and Adak, 2002] through introduction of a time-
varying effect in form of a step function. Here, R²sch is applied as model-selection 
criterion to derive the number of necessary steps of the time-varying effect. 
It is also possible to extend the definition of R²sch to weighted settings, such as for 
case-cohort data. This setting offers the possibility to reduce genotyping costs 
within large cohorts through sampling of a population-representative subcohort and 
inclusion of all cases, i.e. all non-censored individuals. Hence, sampling weights 
are assigned to each subject, for which it is necessary to account in estimation. 
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Different weighting schemes and robust variance estimators for this kind of study 
have been proposed [Therneau and Li, 1999]. Again, the direct connection of R²sch 
to the score function allows for computation of this criterion. For the other criteria, 
adaptation to the weighted setting with possible cluster definitions for cases that are 
entered twice (as random sample from the cohort and as part of the case sample) 
is less clear and needs more research. A description of a KORA case-cohort, which 
is defined for incident cases of coronary heart disease and type 2 diabetes surveys 
S1, S2 and S3 is available [Thorand et al., 2005]. Application of R²sch to genetic 
association studies in the KORA case-cohort is planned. 
Another major advantage is the possibility to calculate partial coefficients, which 
also suggests its application for model selection. The partial coefficient calculated 
for the genetic variants draws a possible connection to the estimation of heritability 
in family studies. Details and an overview of possible extensions and applications 
can be found in [Xu, 1996], [O'Quigley and Xu, 2001], and [O'Quigley and Xu, 
2006]. 
Its high flexibility and especially the possibility to calculate partial coefficients is of 
major interest for genetic association studies, where the genetic effect often has to 
be judged in presence of non-genetic covariates. Adopting the general definition of 
partial coefficients for R²sch [O'Quigley and Xu, 2006], the impact of the genetic 
variants on the outcome’s variation in presence of environmental covariates can be 
established as follows: Let Xg1,…, Xgm be the subset of m genetic covariates and 
Xe1,…Xek be k environmental covariates. With Xβˆ  being the vector of estimations βˆ  
from the model including covariates X, the partial R²sch for the genetic covariates can 
then be calculated as: 
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Partial coefficients allow for closer investigation of model building procedures which 
include, for example, stepwise addition of sets of components, i.e. genetic covariates 
in step one, environmental covariates in step two and gene-environment interactions 
in the third step. In this case, the additional information obtained from the set of 
gene-environment interactions can be judged. Unfortunately, no definition of partial 
coefficients is currently available for any of the other criteria investigated in this study. 
Due to the lack of association of the SNPs investigated in the real data example, no 
contribution of the candidates was detected through calculation of these partial 
coefficients in adjusted mortality analysis except for the artificially generated SNPs. 
Highest values were obtained for the ”extremely lethal” SNP, where partial 
coefficients of R²sch for the additive, dominant and recessive effect model (adjusted 
for age and sex) were calculated as 82.58%, 76.63% and 65.33%, respectively. 
Hence, most of the variation is explained by the genetic covariate alone. Comparison 
of the partial coefficients for the different genetic effect models as in a model building 
situation would here clearly favour the true additive effect coding over the two 
dichotomous variants. 
 
3.6 Conclusion 
The present study showed that none of the investigated criteria proposed for 
judgement of the impact of covariates on survival phenotypes perfectly fulfilled our 
requirements, which also shows why no general recommendation is available, yet. 
The limitation behaviour of kd.norm and V were found to be major problems for 
interpretation as percentage. Altogether, our requirements were best fulfilled by R²sch 
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which is also closest related to estimation in the Cox model and the definition of 
classical R² from linear regression. 
Therefore, R²sch is recommended as a powerful and highly flexible tool for 
quantification of the impact of genetic variants on survival phenotypes. The extensive 
simulation settings also indicate that this recommendation may not only be restricted 
to genetic association studies but also account for general epidemiologic studies. 
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Summary 
Reporting the impact of genetic variants on diseases by means of a percentage of 
impact has become a standard question in genetic epidemiological studies. In case 
of cross-sectional studies with continuous phenotypes or case-control studies, 
measures like R² or derivations are already available. They allow quantifying the 
impact of genetic variants by a measure of percentage of explained variation in the 
phenotype. For survival phenotypes (e.g. mortality or incidence), however, the 
definition of a comparable criterion is still unclear. Therefore, genetic variants are 
usually only judged through effect size estimates and p-values when they are 
analysed in their association to survival phenotypes.  
The aim of this thesis was to identify the criterion which suits best for quantification of 
the impact of genetic variants on survival phenotypes, similar to classical R². For 
none of the investigated criteria, investigations focusing on applicability in genetic 
association analysis, with the special character of genetic variants as statistical 
covariates, are available, yet.  
In first instance, a thorough literature search was performed. It revealed three criteria 
that were generally considered eligible for measuring of the impact of genetic 
variants as percentage – comparable to a measure of explained variation. 
The three identified criteria measure: 
(1) difference between deviance residuals (kd.norm) 
(2) variation of survival curves (V) 
(3) variation of Schoenfeld residuals (R²sch). 
These were subsequently compared in their performance for SNP data through 
thorough simulation studies with a variety of scenarios (with respect to phenotype 
and genetic variants) and application to KORA mortality data. 
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The focus of the evaluation was set on the following predefined requirements: 
(a) reasonable criteria values in the range [0;1] in order to allow for interpretation 
as percentage of prediction quality 
(b) increasing values with increasing genetic effect size 
(c) independence of the percentage of censored observations in the data 
 
However, none of the investigated criteria perfectly fulfilled these requirements. In the 
simulation studies, the deviance residuals’ criterion showed high dependence on the 
censoring percentage and is not generally limited to the range [0; 1]. The second 
criterion (variation of survival curves) hardly reached values above 60%. The 
requirements were best fulfilled by the criterion based on Schoenfeld residuals. 
Additionally to the good performance in genetic simulation studies, and application to 
mortality data, a variety of possible extensions and applications are available for this 
criterion. Therefore, it is recommended as a powerful and highly flexible tool for 
judgement of the impact of genetic variants in genetic association studies with 
survival outcome, which, in addition, is relatively easy to calculate. 
Therefore, it is now possible to fill the gap of a missing criterion like R² for judgment 
of the impact of genetic variants in analysis of survival phenotypes. Furthermore, a 
deeper insight into the Cox proportional hazards model was gained. Therefore, some 
general problems which may occur in genetic association analysis with survival 
phenotypes could be identified. 
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Zusammenfassung 
Die Frage nach der Bedeutung genetischer Varianten für Erkrankungen im Sinne 
einer Prozentzahl des Einflusses ist inzwischen zu einer Standardfrage genetische 
epidemiologischer Studien geworden. Bei Querschnittsstudien mit kontinuierlichen 
Phänotypen oder Fallkontrollstudien stehen bereits Maße wie R² o.ä. zur Verfügung. 
Diese erlauben die Beurteilung des Einflusses der genetischen Varianten im Sinne 
der erklärten Varianz. Für Survivalphänotypen (wie z.B. Mortalität oder Inzidenz) ist 
die Definition eines vergleichbaren Kriteriums allerdings noch unklar. Somit 
beschränkt sich die Beurteilung genetischer Einflüsse bei der Analyse von 
Survivalphänotypen häufig auf Effektstärken und p-Werte. 
Ziel dieser Arbeit war es, ein Kriterium zu identifizieren, das am ehesten dazu 
geeignet ist, genetische Varianten im Sinne eines klassischen R²-Kriteriums in ihrem 
Einfluss auf Survivalphänotypen zu beurteilen. Für keines der betrachteten Kriterien 
wurden bisher Untersuchungen hinsichtlich der Eignung für genetische 
Assoziationsanalysen durchgeführt, die sich durch Besonderheiten der genetischen 
Varianten als Kovariablen im statistischen Sinne auszeichnen. 
Zunächst wurde dazu eine umfangreiche Literatursuche durchgeführt, über die drei 
Kriterien identifiziert wurden, die prinzipiell geeignet schienen, eine Interpretation des 
genetischen Einflusses im Sinne eines Maßes erklärter Varianz zu ermöglichen.  
 
Die drei identifizierten Kriterien beruhen auf: 
(1) Differenz zwischen Devianzresiduen (kd.norm) 
(2) Variation individueller Survivalkurven (V) 
(3) Variation von Schoenfeld-Residuen (R²sch). 
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Diese wurden anschließend anhand von umfangreichen Simulationsstudien mit einer 
Vielfalt an Szenarien (bzgl. Phänotyp und genetischer Varianten) sowie einer 
Anwendung auf KORA-Mortalitätsdaten hinsichtlich ihrer Eignung für SNP-
Assoziationsstudien untersucht. Bei der Beurteilung standen die folgenden im Vorfeld 
definierten Anforderungen im Vordergrund: 
(a) sinnvolle Werte im Bereich [0;1] um eine Interpretation als Prozent erklärter 
Variation zu gewährleisten 
(b) größere Werte mit wachsender Effektstärke 
(c) Unabhängigkeit vom Zensierungsanteil in den Daten 
 
Die Untersuchung zeigte, dass keines der verwendeten Kriterien gänzlich diese 
Anforderungen erfüllte. Das auf Devianzresiduen basierende Kriterium zeigte in den 
Simulationsstudien eine starke Abhängigkeit vom Zensierungsanteil in den Daten 
und hielt keine generelle Limitierung des Wertebereichs auf [0;1] ein. Das zweite 
Kriterium (Variation individueller Survivalkurven) erreichte selten Werte über 60%. 
Die gestellten Anforderungen wurden am besten durch das auf Schoenfeld-Residuen 
basierende Kriterium erfüllt. Zusätzlich zu der positiven Beurteilung im Rahmen der 
genetischen Simulationsstudien und der Anwendung auf Mortalitätsdaten, stehen für 
dieses Kriterium eine Vielzahl an Anwendungsmöglichkeiten und möglicher 
Erweiterungen zur Verfügung. Daher wird es als starkes und hoch flexibles Maß zur 
Beurteilung des Einflusses genetischer Varianten in Assoziationstudien mit Survival-
Phänotypen empfohlen, das zudem noch relativ einfach zu berechnen ist. 
Hiermit ist es nun möglich, die Lücke eines fehlenden Kriteriums zur Beurteilung des 
Einflusses genetischer Varianten im Sinne eines R² zu füllen. Zusätzlich konnte ein 
tieferer Einblick in das Cox proportional hazards Modell gewonnen werden. Daher 
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konnten einige generelle Probleme, die bei genetischen Assoziationsstudien mit 
Survivalphänotypen auftreten können, identifiziert werden. 
References 88 
 
References 
Kaplan EL, Meier P. 1958. Nonparametric estimation from incomplete observations. 
Journal of the American Statistical Association 53:457-481. 
Cox DR. 1972. Regression models and life-tables (with discussion). Journal of the 
Royal Statistical Society: Series B 34:187-220. 
Cox DR. 1975. Partial likelihood. Biometrika 62:269-276. 
Grambsch PM, Therneau TM. 1994. Proportional hazards tests and diagnostics 
based on weighted residuals. Biometrika 81:515-526. 
Frazer KA, Ballinger DG, Cox DR et al. 2007. A second generation human haplotype 
map of over 3.1 million SNPs. Nature 449(7164):851-861. 
Vollmert C, Hahn S, Lamina C et al. 2007. Calpain-10 variants and haplotypes are 
associated with polycystic ovary syndrome in Caucasians. Am.J.Physiol 
Endocrinol.Metab 292(3):E836-E844. 
Heid IM, Lamina C, Küchenhoff H et al. 2008. Estimating the SNP Genotype 
Misclassification from Routine Double Measurements in a Large 
Epidemiological Sample. American Journal of Epidemiology . 
Stram DO, Haiman CA, Hirschhorn JN et al. 2003. Choosing haplotype-tagging 
SNPS based on unphased genotype data using a preliminary sample of 
89 References 
 
unrelated subjects with an example from the Multiethnic Cohort Study. 
Hum.Hered. 55(1):27-36. 
Hattersley AT, McCarthy MI. 2005. What makes a good genetic association study? 
Lancet 366(9493):1315-1323. 
Dawn TM, Barrett JH. 2005. Genetic linkage studies. Lancet 366(9490):1036-1044. 
Spielman RS, McGinnis RE, Ewens WJ. 1993. Transmission test for linkage 
disequilibrium: the insulin gene region and insulin-dependent diabetes mellitus 
(IDDM). Am.J.Hum.Genet. 52(3):506-516. 
Cordell HJ, Clayton DG. 2005. Genetic association studies. Lancet 366(9491):1121-
1131. 
Kaprio J. 2000. Science, medicine, and the future. Genetic epidemiology. BMJ 
320(7244):1257-1259. 
Burton PR, Tobin MD, Hopper JL. 2005. Key concepts in genetic epidemiology. 
Lancet 366(9489):941-951. 
Schaid DJ. 2004. Evaluating associations of haplotypes with traits. Genet.Epidemiol. 
27(4):348-364. 
Cook NR. 2007. Use and misuse of the receiver operating characteristic curve in risk 
prediction. Circulation 115(7):928-935. 
References 90 
 
Rosthoj S, Keiding N. 2004. Explained variation and predictive accuracy in general 
parametric statistical models: the role of model misspecification. Lifetime Data 
Analysis 10(4):461-472. 
Kvalseth TO. 1985. Cautionary Note About R². The American Statistician 39(4):279-
285. 
Van Houwelingen JC, Le Cessie S. 1990. Predictive value of statistical models. 
Stat.Med. 9(11):1303-1325. 
Nagelkerke NJD. 1991. A note on a general definition of the coefficient of 
determination. Biometrika 78(3):691-692. 
Wild S, Roglic G, Green A, Sicree R, King H. 2004. Global prevalence of diabetes: 
estimates for the year 2000 and projections for 2030. Diabetes Care 
27(5):1047-1053. 
Bell CG, Walley AJ, Froguel P. 2005. The genetics of human obesity. Nat.Rev.Genet. 
6(3):221-234. 
Capri M, Salvioli S, Sevini F et al. 2006. The genetics of human longevity. 
Ann.N.Y.Acad.Sci. 1067:252-263. 
Schemper M, Stare J. 1996. Explained variation in survival analysis. Stat.Med. 
15(19):1999-2012. 
91 References 
 
Harrell FE, Jr. Regression Modeling Strategies: With Applications to Linear Models, 
Logistic Regression, and Survival Analysis. Springer: New York, 2001. 
Maddala G.S. Limited-Dependent and Qualitative Variables in Econometriocs. 
Cambridge University Press: Cambridge, UK, 1983. 
Magee L. 1990. R² meaasures based on Wald and likelihood ratio joint significance 
tests. The American Statistician 44:250-253. 
Kent TJ, O'Quigley J. 1988. Measures of dependence for censored survival data. 
Biometrika 75:525-534. 
Somers RH. 1962. A new asymmetric measure of association for ordinal variables. 
American Sociological Review 27:799-811. 
Harrell FE, Jr., Califf RM, Pryor DB, Lee KL, Rosati RA. 1982. Evaluating the yield of 
medical tests. JAMA 247(18):2543-2546. 
Sauerbrei W, Hubner K, Schmoor C, Schumacher M. 1997. Validation of existing and 
development of new prognostic classification schemes in node negative breast 
cancer. German Breast Cancer Study Group. Breast Cancer Res.Treat. 
42(2):149-163. 
Royston P, Sauerbrei W. 2004. A new measure of prognostic separation in survival 
data. Stat.Med. 23(5):723-748. 
References 92 
 
Graf E, Schmoor C, Sauerbrei W, Schumacher M. 1999. Assessment and 
comparison of prognostic classification schemes for survival data. Stat.Med. 
18(17-18):2529-2545. 
Stark, M. 1997. Beurteilungskriterien für die Güte von Modellen zur Analyse von 
Überlebenszeiten. Dissertation. Berlin.  Logos Verlag.  
Schemper M, Henderson R. 2000. Predictive accuracy and explained variation in 
Cox regression. Biometrics 56(1):249-255. 
O'Quigley J, Xu R. 2001. Explained variation in Cox regression. In: Crowley J. (ed)  
Handbook of Statistics in Clinical Oncology. Marcel Dekker, Inc.: pp 397-410. 
Therneau TM, Grambsch PM, Fleming TR. 1990. Martingale-based residuals for 
survival models. Biometrika 77(1):147-160. 
Gerds TA, Schumacher M. 2006. Consistent estimation of the expected Brier score in 
general survival models with right-censored event times. Biom.J. 48(6):1029-
1040. 
Schemper M, Smith TL. 1996. A note on quantifying follow-up in studies of failure 
time. Control Clin.Trials 17(4):343-346. 
Altman DG, De Stavola BL, Love SB, Stepniewska KA. 1995. Review of survival 
analyses published in cancer journals. Br.J.Cancer 72(2):511-518. 
93 References 
 
Schoenfeld DA. 1982. Partial residuals for the proportional hazards regression 
model. Biometrika 69(1):239-241. 
O'Quigley J, Flandre P. 1994. Predictive capability of proportional hazards 
regression. Proc.Natl.Acad.Sci.U.S.A 91(6):2310-2314. 
Andersen PK, Christensen E, Fauerholdt L, Schlichting P. 1983. Measuring 
prognosis using the proportional hazards model. Scand.J.Statist. 10:49-52. 
Bender R, Augustin T, Blettner M. 2005. Generating survival times to simulate Cox 
proportional hazards models. Stat.Med. 24(11):1713-1723. 
R Development Core Team. R: A Language and Environment for Statistical 
Computing.  Vienna, Austria, R Foundation for Statistical Computing.  
Holle R, Happich M, Lowel H, Wichmann HE. 2005. KORA--a research platform for 
population based health research. Gesundheitswesen 67 Suppl 1:S19-S25. 
Emigh T. 1980. Comparison of tests for Hardy-Weinberg Equilibrium. Biometrics 
36:627-642. 
Li J, Ji L. 2005. Adjusting multiple testing in multilocus analyses using the 
eigenvalues of a correlation matrix. Heredity 95(3):221-227. 
Schumacher M, Graf E, Gerds T. 2003. How to assess prognostic models for survival 
data: a case study in oncology. Methods Inf.Med. 42(5):564-571. 
References 94 
 
Korn EL, Simon R. 1990. Measures of explained variation for survival data. Stat.Med. 
9(5):487-503. 
Xu, R. 1996. Inference for the proportional hazards model. Dissertation.  University of 
California, San Diego.  
Xu R, O'Quigley J. 1999. A R-2 type measure of dependence for proportional 
hazards models. Journal of Nonparametric Statistics 12(1):83-107. 
Therneau TM, Grambsch PM. Modeling Survival Data. Extending the Cox Model. 
Springer-Verlag: New York Berlin Heidelberg, 2000. 
Xu R, Adak S. 2002. Survival analysis with time-varying regression effects using a 
tree-based approach. Biometrics 58(2):305-315. 
Therneau TM, Li H. 1999. Computing the Cox model for case cohort designs. 
Lifetime.Data Anal. 5(2):99-112. 
Thorand B, Schneider A, Baumert J et al. 2005. Case-cohort studies: an effective 
design for the investigation of biomarkers as risk factors for chronic diseases--
demonstrated by the example of the MONICA/KORA Augsburg Case-Cohort 
Study 1984-2002. Gesundheitswesen 67 Suppl 1:S98-102. 
O'Quigley J, Xu R. 2006. Explained Variation in Proportional Hazards Regression. In: 
Crowley J., Ankerst D (eds)  Handbook of Statistics in Clinical Oncology. Boca 
Raton: Chapman & Hall/CRC. 
95 Appendix 
 
 
 
Appendix 
 
Appendix 96 
 
A1. List of publications and presentations 
List of oral presentations 
Seminar, Charité, Institut für Sozialmedizin, Epidemiologie und 
Gesundheitsökonomie, Nov. 2007, Berlin: „Einführung in die genetische 
Epidemiologie” 
Kongress “Medizin und Gesellschaft”, Sept. 2007, Augsburg: “Quantification of the 
contribution of genetic variants in association analysis with survival outcome: three 
methods in comparison” 
Seminar, Georg-August-Universität, Göttingen, Department of Genetic Epidemiology, 
Jan. 2006: “Judging explained variation in survival models” 
Airgene Workshop, Oct. 2005, GSF, Neuherberg: “Haplotypes and the CRP gene” 
Seminar, TU München, Institute for Medical Statistics and Epidemiology, Apr. 2004, 
“Gütekriterien in der Survivalanalyse” 
SFB 368, Workshop Höhenried, Jun. 2003, “Modellierung komplexer Interaktionen in 
der Survivalanalyse“ 
97 Appendix 
 
Poster presentations 
48th Cardiovascular Disease Epidemiology and Prevention Conference, and Nutrition, 
Physical Activity and Metabolism Conference.  13.03-15.03.2008, Colorado Springs, 
Colorado, USA. Circulation 2008;117: e256 (P221): “Effect of macrophage MIF gene 
variants and serum concentrations on the risk for coronary heart disease: results 
from the MONICA/KORA Augsburg Study, 1984-2002”, authors: Herder C, Klopp N, 
Baumert J, Müller M, Khuseyinova N, Meisinger C, Martin S, Illig T, Koenig W, 
Thorand B 
  
48th Cardiovascular Disease Epidemiology and Prevention Conference, and Nutrition, 
Physical Activity and Metabolism Conference.  13.03-15.03.2008, Colorado Springs, 
Colorado, USA. Circulation 2008;117: e255 (P215): “Interleukin-18 gene 
polymorphisms, interleukin-18 serum concentrations and risk of coronary heart 
disease: results from the MONICA/KORA Augsburg case-cohort study, 1984-2002”, 
authors: Thorand B, Baumert J, Herder C, Klopp N, Kolz M, Khuseyinova N, Müller 
M, Loewel H, Illig T, Koenig W  
 
Jahrestagung der deutschen Gesellschaft für Kardiologie, Mannheim 27.03.-
29.03.2008: “Interleukin-18 gene polymorphisms and incident coronary heart disease 
in middle-aged men and women: results from the MONICA/KORA Augsburg case-
cohort study, 1984-2002”, authors: Thorand B, Baumert J, Herder C, Klopp N, Kolz 
M, Khuseyinova N, Müller M, Meisinger C, Illig T, Koenig W 
 
XXVII Congress of the European Society of Cardiology, Vienna, 01.09.-05.09.2007. 
Eur Heart J 2007;28(Abstract Supplement):691 (P4112): “Effect of macrophage MIF 
Appendix 98 
 
gene variants and serum concentrations on the risk for type 2 diabetes and coronary 
heart disease: results from the MONICA/KORA Augsburg Study, 1984-2002.”, 
authors: Herder C, Klopp N, Baumert J, Müller M, Khuseyinova N, Meisinger C, 
Martin S, Illig T, Koenig W, Thorand B.  
  
.XXVII Congress of the European Society of Cardiology, Vienna, 01.09.-05.09.2007. 
Eur Heart J 2007;28(Abstract Supplement):692 (P4115): “Interleukin-18 gene 
polymorphisms, interleukin-18 serum concentrations and risk of coronary heart 
disease: results from the MONICA/KORA Augsburg case-cohort study, 1984-2002”, 
authors: Thorand B, Baumert J, Herder C, Klopp N, Kolz M, Khuseyinova N, Müller 
M, Löwel H, Illig T, Koenig W. 
Congress „Statistik unter einem Dach“, Bielefeld, Mar. 2007: „Quantifying the 
contribution of genetic variants in association analysis with survival outcome: three 
methods in comparison“, authors: Martina Müller, Helmut Küchenhoff, Dörthe 
Malzahn, Heike Bickeböller(4), Thomas Illig, H.-Erich Wichmann, Iris M. Heid 
47th Annual Conference on Cardiovascular Disease Epidemiology and Prevention. 
28.02-03.03.07, Orlando, USA. Circulation 2007;115 (8): e299 (P367): “No 
association between C-reactive protein (CRP) gene polymorphisms, CRP haplotypes 
and incident type 2 diabetes mellitus (T2DM) in middle-aged men and women: 
results from the MONICA/KORA Augsburg case-cohort study, 1984-2002”, authors: 
Khuseyinova N, Baumert J, Müller M, Klopp N, Kolz M, Meisinger C, Illig T, Thorand 
B, Koenig W.  
 
Symposium of the German National Genome Research Network (NGFN) 2007, 
Heidelberg, Germany, 10.11-11.11.2007: “Interleukin-18 gene polymorphisms, 
99 Appendix 
 
interleukin-18 serum concentrations and risk of coronary heart disease: results from 
the MONICA/KORA Augsburg case-cohort study, 1984-2002”, authors: Thorand B, 
Baumert J, Herder C, Klopp N, Kolz M, Khuseyinova N, Müller M, Loewel H, Illig T, 
Koenig W 
 
Symposium of the German National Genome Research Network (NGFN) 2007, 
Heidelberg, Germany, 10.11-11.11.2007: “RANTES/CCL5 gene polymorphisms, 
serum concentrations and incident type 2 diabetes: results from the MONICA/KORA 
Augsburg case-cohort study, 1984-2002”, authors: Herder C, Illig T, Baumert J, 
Müller M, Klopp N, Khuseyinova N, Meisinger C, Poschen U, Martin S, Koenig W, 
Thorand B 
 
Symposium of the German National Genome Research Network (NGFN) 2007, 
Heidelberg, Germany, 10.11-11.11.2007: “Genetic variants in the Upstream 
Stimulatory Factor 1 (USF1) gene are associated with lipid parameters and T2DM in 
German Caucasians: Results from the MONICA/KORA Augsburg case-cohort study, 
1984-2002”, authors: Holzapfel C, Baumert J, Grallert H, Müller M, Khuseyinova N, 
Herder C, Thorand B, Hauner H, Wichmann HE, Koenig W, Illig T, Klopp N 
 
Symposium of the German National Genome Research Network (NGFN) 2006, 
Heidelberg, Germany, 25.11-26.11.2006: „Quantifying the contribution of genetic 
variants in association analysis with survival outcome: three methods in comparison“, 
authors: Martina Müller, Helmut Küchenhoff, Dörthe Malzahn, Heike Bickeböller(4), 
Thomas Illig, H.-Erich Wichmann, Iris M. Heid 
 
Appendix 100 
 
Symposium of the German National Genome Research Network (NGFN) 2006, 
Heidelberg, Germany, 25.11-26.11.2006: “Effect of macrophage migration inhibitory 
factor (MIF) gene variants and serum concentrations on the risk for type 2 diabetes 
and coronary heart disease: Results from the MONICA/KORA Augsburg Study, 
1984-2002”, authors: Herder C, Klopp N, Baumert J, Müller M, Khuseyinova N, 
Meisinger Ch, Martin S, Illig T, Koenig W Thorand B. 
 
 
Publications 
Petter Lennart Seve Ljungman, M.D.; Tom Bellander, PhD; Fredrik Nyberg, MPH MD 
PhD; Erik Lampa, MSc; Bénédicte Jacquemin, MD PhD; Melanie Kolz, MSc; Timo 
Lanki, PhD; John Mitropoulos, MD; Martina Müller, MSc; Sally Picciotto, PhD; 
Riccardo Pistelli, MD; Regina Rückerl, MSc; Wolfgang Koenig, MD Prof; Annette 
Peters, PhD MPH: DNA variants, plasma levels and variability of Interleukin-6 in 
myocardial infarction survivors: Results from the AIRGENE study. Thrombosis 
Research (accepted) 
Holzapfel C, Baumert J, Grallert H, Mueller AM, Thorand B, Khuseyinova N, Herder 
C, Meisinger C, Hauner H, Wichmann H, Koenig W, Illig T, Klopp N: Genetic variants 
in the USF1 gene are associated with LDL cholesterol levels and incident T2DM in 
women: results from the MONICA/KORA Augsburg case-cohort study, 1984-2002. 
Eur J Endocrinol, 2008 Oct; 159(4): 407-16.  
Jacquemin B, Antoniades C, Nyberg F, Plana E, Müller M, Greven S, Salomaa V, 
Sunyer J, Bellander T, Chalamandaris AG, Pistelli R, Koenig W, Peters A: Common 
Genetic Polymorphisms And Haplotypes Of Fibrinogen -a, -ß And -γ Chains Affect 
101 Appendix 
 
Fibrinogen Levels And The Response To Proinflammatory Stimulation In Myocardial 
Infarction Survivors: The AIRGENE Study. Journal of the American College of 
Cardiology. 2008 Sep 9;52(11):941-52. 
Heid IM, Boes E, Müller AM, Kollerits B, Lamina C, Coassin S, Gieger C, Döring A, 
Klopp N, Frikke-Schmidt R, Tybjærg-Hansen A, Brandstätter A, Luchner A, Meitinger 
T, Wichmann HE, Kronenberg F: A Genome-Wide Association Analysis of HDL-
Cholesterol in the Population-Based KORA Study Sheds New Light on Intergenic 
Regions. Circulation: Cardiovascular Genetics. 2008 Oct;1:10-20. 
Herder C, Illig T, Baumert J, Müller M, Klopp N, Khuseyinova N, Meisinger C, 
Poschen U, Martin S, Koenig W, Thorand B: RANTES/CCL5 gene polymorphisms, 
serum concentrations, and incident type 2 diabetes: results from the MONICA/KORA 
Augsburg case-cohort study, 1984-2002. Eur J Endocrinol. 2008 May;158(5):R1-5.  
Heid I, Lamina C, Küchenhoff H, Fischer G, Klopp N, Kolz M, Grallert H, Vollmert C, 
Wagner S, Huth C, Müller J, Müller M, Hunt S, Peters A, Paulweber B, Wichmann H, 
Kronenberg F, Illig T.: Estimating the Single Nucleotide Polymorphism Genotype 
Misclassification From Routine Double Measurements in a Large Epidemiologic 
Sample. American Journal of Epidemiology . 2008 Sep 12. Epub ahead of print. 
Müller, M., Döring, A., Küchenhoff, H., Lamina, C., Malzahn, D., Bickeböller, H., 
Vollmert, C., Klopp, N., Meisinger, C., Heinrich, J., Kronenberg, F., Wichmann, H.-E., 
Heid, I.M.: Quantifying the contribution of genetic variants for survival phenotypes. 
Genetic Epidemiology. 32(6), 574-585, 2008 
Kolz, M., Baumert, J., Müller, M., Khuseyinova, N., Klopp, N., Thorand, B., Meisinger, 
C., Herder, C., Koenig, W. and Illig, T.: Association between variations in the TLR4 
Appendix 102 
 
gene and incident type 2 diabetes is modified by the ratio of total cholesterol to HDL-
cholesterol. BMC Medical Genetics. 9(1), 9, 2008 
Herder, C., Illig, T., Baumert, J., Müller, M., Klopp, N., Khuseyinova, N., Meisinger, 
C., Martin, S., Thorand, B., Koenig, W.: Macrophage migration inhibitory factor (MIF) 
and risk for coronary heart disease: Results from the MONICA/KORA Augsburg 
Case-Cohort Study, 1984-2002. Atherosclerosis. 2008 Jan 31. Epub ahead of print.  
Herder, C., Klopp, N., Baumert, J., Müller, M., Khuseyinova, N., Meisinger, C., Martin, 
S., Illig, T., Koenig, W., Thorand, B.: Effect of macrophage migration inhibitory factor 
(MIF) gene variants and MIF serum concentrations on the risk of type 2 diabetes: 
results from the MONICA/KORA Augsburg Case Cohort Study, 1984-2002. 
Diabetologia, 2008 Feb;51(2):276-84. 
Kolz, M., Koenig, W., Müller, M., Andreani, M., Greven, S., Illig, T., Khuseyinova, N., 
Panagiotakos, D., Pershagen, G., Salomaa, V., Sunyer, J., Peters, A., for the 
AIRGENE Study Group: DNA variants, plasma levels and variability of C-reactive 
protein in Myocardial infarction survivors: results from the AIRGENE study. Eur Heart 
J. 2008 May;29(10):1250-8 
Schaeffer L, Gohlke H, Müller M, Heid IM, Palmer LJ, Kompauer I, Demmelmair H, 
Illig T, Koletzko B, Heinrich J.: Common genetic variants of the FADS1 FADS2 gene 
cluster and their reconstructed haplotypes are associated with the fatty acid 
composition in phospholipids. Hum Mol Genet. 2006 Jun 1;15(11):1745-56. 
Napieralski R, Ott K, Kremer M, Specht K, Vogelsang H, Becker K, Müller M, Lordick 
F, Fink U, Rüdiger Siewert J, Höfler H, Keller G.: Combined GADD45A and thymidine 
103 Appendix 
 
phosphorylase expression levels predict response and survival of neoadjuvant-
treated gastric cancer patients. Clin Cancer Res. 2005 Apr 15;11(8):3025-31. 
Mueller, M.: Goodness-of-fit criteria for survival data. Discussion Paper 382. 
Sonderforschungsbereich 368, Ludwig-Maximilians-Universität, München, 2004. 
Ott K, Vogelsang H, Mueller J, Becker K, Müller M, Fink U, Siewert JR, Höfler H, 
Keller G.: Chromosomal instability rather than p53 mutation is associated with 
response to neoadjuvant cisplatin-based chemotherapy in gastric carcinoma. Clin 
Cancer Res. 2003 Jun;9(6):2307-15. 
Müller, M., Ulm, K. (2003): Implementation of complex interactions in a Cox 
regression framework. Discussion Paper 363. Sonderforschungsbereich 368, 
Ludwig-Maximilians-Universität, München, 2003. 
Appendix 104 
 
A2. Curriculum vitae 
Surname: Müller 
First name: Andrea Martina 
Date / place of birth: 20.08.1974, München 
Marital status: single 
Academic Education: 
Since Sept. 2004 PhD student at Institute of Medical Information Processing, 
Biometry and Epidemiology, Ludwig-Maximilians-Universität, 
Chair of Epidemiology, research unit 'Genetic Epidemiology', 
Neuherberg, Germany.  
2001 Diploma in statistics, Ludwig-Maximilians-Universität München, 
Germany. 
1999/2000 Course of practical work in biology “Botanisches Großpraktikum” 
1999 Course of practical work in biology “Tropenbotanik” 
1997/1998 Course of practical work in statistics “Immobilienmarktanalyse” 
1997 Course of practical work in biology “Artenvielfalt in der Botanik” 
1996 Course of practical work in biology “Botanisches 
Grundpraktikum” 
1994/1995 Course of practical work in biology “Genetisches 
Grundpraktikum” 
105 Appendix 
 
1994 Begin of studies in statistics with a focus of applications in 
biology, Ludwig-Maximilians-Universität München, Germany. 
1994 Qualification for admission to university 
 
Work Experience: 
Since July 2008 Statistical researcher and consultant at the Department of 
Internal Medicine I (Cardiology), Klinikum Grosshadern, Ludwig-
Maximilians-Universität, Munich, Germany 
2004-2008 Statistical researcher and consultant at GSF-Institute of 
Epidemiology (renamed 2008 Helmholtz Zentrum München) and 
Institute of Medical Information Processing, Biometry and 
Epidemiology, Ludwig-Maximilians-Universität, Chair of 
Epidemiology, research unit 'Genetic Epidemiology', 
Neuherberg, Germany.  
2001 – 2004 Statistical researcher and consultant with a focus on cancer 
research, Institute for Medical Statistics and Epidemiology 
(IMSE), research unit "Prognostic Factors", TU München, 
Germany.  
1999 – 2001 Student assistant and statistical consultant, Institute for Medical 
Statistics and Epidemiology (IMSE), research unit “Prognostic 
Factors”, TU München, Germany. 
Appendix 106 
 
1999 – 2001 Involvement into fieldwork and study design as interviewer for 
several research projects on infrastructure by the company 
Socialdata, Munich. 
 
